false Q2 --09-30 0001527613 0001527613 2025-10-01 2026-03-31 0001527613 2026-05-06 0001527613 2026-03-31 0001527613 2025-09-30 0001527613 us-gaap:RelatedPartyMember 2026-03-31 0001527613 us-gaap:RelatedPartyMember 2025-09-30 0001527613 2026-01-01 2026-03-31 0001527613 2025-12-05 0001527613 2025-12-04 0001527613 2025-01-01 2025-03-31 0001527613 2024-10-01 2025-03-31 0001527613 us-gaap:CommonStockMember 2025-09-30 0001527613 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001527613 IMG:SubscriptionReceivableMember 2025-09-30 0001527613 us-gaap:RetainedEarningsMember 2025-09-30 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001527613 us-gaap:NoncontrollingInterestMember 2025-09-30 0001527613 us-gaap:CommonStockMember 2025-12-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001527613 IMG:SubscriptionReceivableMember 2025-12-31 0001527613 us-gaap:RetainedEarningsMember 2025-12-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001527613 us-gaap:NoncontrollingInterestMember 2025-12-31 0001527613 2025-12-31 0001527613 us-gaap:CommonStockMember 2024-09-30 0001527613 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001527613 IMG:SubscriptionReceivableMember 2024-09-30 0001527613 us-gaap:RetainedEarningsMember 2024-09-30 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001527613 us-gaap:NoncontrollingInterestMember 2024-09-30 0001527613 2024-09-30 0001527613 us-gaap:CommonStockMember 2024-12-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001527613 IMG:SubscriptionReceivableMember 2024-12-31 0001527613 us-gaap:RetainedEarningsMember 2024-12-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001527613 us-gaap:NoncontrollingInterestMember 2024-12-31 0001527613 2024-12-31 0001527613 us-gaap:CommonStockMember 2025-10-01 2025-12-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2025-10-01 2025-12-31 0001527613 IMG:SubscriptionReceivableMember 2025-10-01 2025-12-31 0001527613 us-gaap:RetainedEarningsMember 2025-10-01 2025-12-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-10-01 2025-12-31 0001527613 us-gaap:NoncontrollingInterestMember 2025-10-01 2025-12-31 0001527613 2025-10-01 2025-12-31 0001527613 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001527613 IMG:SubscriptionReceivableMember 2026-01-01 2026-03-31 0001527613 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001527613 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001527613 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001527613 IMG:SubscriptionReceivableMember 2024-10-01 2024-12-31 0001527613 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-01 2024-12-31 0001527613 us-gaap:NoncontrollingInterestMember 2024-10-01 2024-12-31 0001527613 2024-10-01 2024-12-31 0001527613 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001527613 IMG:SubscriptionReceivableMember 2025-01-01 2025-03-31 0001527613 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001527613 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001527613 us-gaap:CommonStockMember 2026-03-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001527613 IMG:SubscriptionReceivableMember 2026-03-31 0001527613 us-gaap:RetainedEarningsMember 2026-03-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001527613 us-gaap:NoncontrollingInterestMember 2026-03-31 0001527613 us-gaap:CommonStockMember 2025-03-31 0001527613 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001527613 IMG:SubscriptionReceivableMember 2025-03-31 0001527613 us-gaap:RetainedEarningsMember 2025-03-31 0001527613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001527613 us-gaap:NoncontrollingInterestMember 2025-03-31 0001527613 2025-03-31 0001527613 IMG:ZhongyanShangyueTechnologyCoLtdMember 2025-03-10 0001527613 IMG:ShanghaiHuomaoCulturalDevelopmentCoLtdMember 2025-03-10 0001527613 IMG:ZhongyanShangyueTechnologyCoLtdMember 2025-03-27 0001527613 IMG:ShenzhenZhimengQiyangTechnologyCoLtdMember 2026-03-11 0001527613 IMG:ShenzhenZhimengQiyangTechnologyCoLtdMember 2025-08-01 0001527613 IMG:DZRTechLimitedMember 2025-09-23 0001527613 IMG:DZRTechLimitedMember 2026-03-12 0001527613 2025-12-05 2025-12-05 0001527613 IMG:SingaporeLimitedLiabilityMember 2025-10-01 2026-03-31 0001527613 us-gaap:OfficeEquipmentMember 2026-03-31 0001527613 us-gaap:MachineryAndEquipmentMember 2026-03-31 0001527613 us-gaap:CommonStockMember IMG:TwoThousandTwentyFourEquityIncentivePlanMember 2025-10-01 2026-03-31 0001527613 us-gaap:SalesRevenueNetMember IMG:CustomerZNFMember us-gaap:CustomerConcentrationRiskMember 2025-10-01 2026-03-31 0001527613 us-gaap:AccountsReceivableMember IMG:CustomerZNFMember us-gaap:CustomerConcentrationRiskMember 2026-03-31 0001527613 us-gaap:AccountsReceivableMember IMG:CustomerZNFMember us-gaap:CustomerConcentrationRiskMember 2025-10-01 2026-03-31 0001527613 us-gaap:SalesRevenueNetMember IMG:CustomerLXMMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2025-03-31 0001527613 us-gaap:AccountsReceivableMember IMG:CustomerLXMMember us-gaap:CustomerConcentrationRiskMember 2025-03-31 0001527613 us-gaap:AccountsReceivableMember IMG:CustomerLXMMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2025-03-31 0001527613 us-gaap:SalesRevenueNetMember IMG:SupllierYKZSMember us-gaap:SupplierConcentrationRiskMember 2025-10-01 2026-03-31 0001527613 us-gaap:SalesRevenueNetMember IMG:SupllierTTYMember us-gaap:SupplierConcentrationRiskMember 2025-10-01 2026-03-31 0001527613 us-gaap:SalesRevenueNetMember IMG:SupllierACJNMember us-gaap:SupplierConcentrationRiskMember 2025-10-01 2026-03-31 0001527613 us-gaap:SalesRevenueNetMember IMG:SupllierYKYMMember us-gaap:SupplierConcentrationRiskMember 2024-10-01 2025-03-31 0001527613 IMG:WuxiChinaOfficeSpaceMember 2025-10-01 2026-03-31 0001527613 IMG:BocaRatonFloridaOfficeSpaceMember 2025-10-01 2026-03-31 0001527613 IMG:HenanChinaOfficeSpaceMember 2025-10-01 2026-03-31 0001527613 IMG:HenanChinaWarehouseSpaceMember 2025-10-01 2026-03-31 0001527613 IMG:ContractualLeaseTermJanuaryTwentyAndMarchThirtyOneTwoThousandTwentyEightMember 2025-10-01 2026-03-31 0001527613 2024-08-20 0001527613 us-gaap:NonrelatedPartyMember 2024-08-20 0001527613 us-gaap:RelatedPartyMember 2024-08-20 0001527613 2024-10-31 2024-10-31 0001527613 2024-12-12 0001527613 us-gaap:NonrelatedPartyMember 2024-12-12 0001527613 us-gaap:RelatedPartyMember 2024-12-12 0001527613 us-gaap:InvestorMember 2025-03-18 2025-03-18 0001527613 IMG:ConvertibleBondPurchaseAgreementMember 2025-08-21 0001527613 us-gaap:NonrelatedPartyMember 2025-09-30 0001527613 us-gaap:NonrelatedPartyMember 2024-10-01 2025-09-30 0001527613 2025-10-30 2025-10-30 0001527613 IMG:ConvertiblePromissoryNoteMember IMG:WarrantPurchaseAgreementMember 2026-02-11 0001527613 IMG:InitialTrancheConvertiblePromissoryNoteMember IMG:WarrantPurchaseAgreementMember 2026-02-11 0001527613 IMG:SecondTrancheConvertiblePromissoryNoteMember IMG:WarrantPurchaseAgreementMember 2026-02-11 0001527613 IMG:WarrantPurchaseAgreementMember IMG:ConvertiblePromissoryNoteMember 2026-02-11 2026-02-11 0001527613 IMG:InitialTrancheConvertiblePromissoryNoteMember IMG:WarrantPurchaseAgreementMember 2026-02-13 0001527613 IMG:InitialTrancheConvertiblePromissoryNoteMember IMG:WarrantPurchaseAgreementMember 2026-03-21 0001527613 IMG:KimsSubscriptionMember 2026-03-31 0001527613 IMG:KenjiSubscriptionMember 2026-03-31 0001527613 2025-07-01 2025-07-01 0001527613 IMG:CIMGIncAndWewinMember 2025-10-01 2026-03-31 0001527613 us-gaap:NonrelatedPartyMember 2025-10-01 2026-03-31 0001527613 us-gaap:RelatedPartyMember 2025-10-01 2026-03-31 0001527613 2024-10-01 2025-09-30 0001527613 IMG:BeijingYingtianHuyuTechnologyCoLtdMember 2026-03-31 0001527613 us-gaap:TrademarksMember 2026-03-31 0001527613 IMG:SoftwareMember 2026-03-31 0001527613 us-gaap:TrademarksMember 2025-09-30 0001527613 IMG:SoftwareMember 2025-09-30 0001527613 us-gaap:NonrelatedPartyMember 2024-09-30 0001527613 us-gaap:NonrelatedPartyMember 2026-03-31 0001527613 us-gaap:RelatedPartyMember 2024-09-30 0001527613 us-gaap:RelatedPartyMember 2024-10-01 2025-09-30 0001527613 IMG:CIMGAndWewinMember 2025-10-01 2026-03-31 0001527613 country:CN 2025-10-01 2026-03-31 0001527613 country:CN 2024-10-01 2025-03-31 0001527613 country:CN 2026-03-31 0001527613 country:CN 2025-09-30 0001527613 IMG:HomologyOfMedicineAndFoodSeriesMember us-gaap:OperatingSegmentsMember 2025-10-01 2026-03-31 0001527613 IMG:ComputingPowerProductSeriesMember us-gaap:OperatingSegmentsMember 2025-10-01 2026-03-31 0001527613 IMG:MacaProductMember us-gaap:OperatingSegmentsMember 2025-10-01 2026-03-31 0001527613 IMG:OthersUnallocatedHeadquarterCostsMember us-gaap:OperatingSegmentsMember 2025-10-01 2026-03-31 0001527613 us-gaap:OperatingSegmentsMember 2025-10-01 2026-03-31 0001527613 IMG:WanhaiLiuMember 2025-10-01 2026-03-31 0001527613 IMG:TianyongLvMember 2025-10-01 2026-03-31 0001527613 IMG:ShengqingLiMember 2025-10-01 2026-03-31 0001527613 IMG:HongfangXieMember 2025-10-01 2026-03-31 0001527613 IMG:WenlongTongMember 2025-10-01 2026-03-31 0001527613 IMG:WenlongYuMember 2025-10-01 2026-03-31 0001527613 IMG:YujieLiuMember 2025-10-01 2026-03-31 0001527613 IMG:YanliHouMember 2025-10-01 2026-03-31 0001527613 IMG:HongfangXieOneMember 2025-10-01 2026-03-31 0001527613 IMG:WenwenYuMember 2025-10-01 2026-03-31 0001527613 IMG:WenwenYuOneMember 2025-10-01 2026-03-31 0001527613 IMG:WenwenYuMember 2026-03-31 0001527613 IMG:YanliHouMember 2026-03-31 0001527613 IMG:ShengqingLiMember 2026-03-31 0001527613 IMG:HongfangXieMember 2026-03-31 0001527613 IMG:YujieLiuMember 2026-03-31 0001527613 IMG:DadaBusinessTradingCoLimitedMember 2026-03-31 0001527613 IMG:YYTechIncMember 2026-03-31 0001527613 IMG:WenlongTongMember 2026-03-31 0001527613 IMG:XujiaLiuMember 2026-03-31 0001527613 IMG:VmadeCoLimitedMember 2026-03-31 0001527613 IMG:DYTInfoPteLimitedMember 2026-03-31 0001527613 IMG:RRDigitalTechLtdMember 2026-03-31 0001527613 IMG:JoyerInvestmentLimitedMember 2026-03-31 0001527613 IMG:KellyviewInvestmentLimitedMember us-gaap:SubsequentEventMember 2026-04-10 0001527613 us-gaap:SubsequentEventMember 2026-04-10 0001527613 IMG:DundasTechnologyLimitedMember 2026-03-12 0001527613 IMG:KellyviewInvestmentLimitedMember 2026-03-12 0001527613 IMG:CommonStockIssuedOnAugustTwoThousandTwentyFiveMember 2025-10-01 2026-03-31 0001527613 2026-03-30 2026-03-30 0001527613 2026-03-31 2026-03-31 0001527613 IMG:CommonStockIssuedOnNovemberTwoThousandTwentyFiveMember 2025-10-01 2026-03-31 0001527613 us-gaap:CommonStockMember 2026-03-30 2026-03-30 0001527613 us-gaap:CommonStockMember 2026-03-31 2026-03-31 0001527613 us-gaap:PrivatePlacementMember IMG:CommonStockIssuedOnAugustTwoThousandTwentyFiveMember 2025-10-01 2026-03-31 0001527613 us-gaap:PrivatePlacementMember 2026-03-30 2026-03-30 0001527613 us-gaap:PrivatePlacementMember 2026-03-31 2026-03-31 0001527613 us-gaap:PrivatePlacementMember 2025-08-21 0001527613 IMG:CommonStockIssuedOnAugustTwoThousandTwentyFiveMember 2025-09-09 2025-09-09 0001527613 IMG:CommonStockIssuedOnAugustTwoThousandTwentyFiveMember 2025-10-30 2025-10-30 0001527613 us-gaap:CommonStockMember 2025-10-01 2026-03-31 0001527613 us-gaap:PrivatePlacementMember 2025-08-25 0001527613 us-gaap:CommonStockMember srt:MaximumMember us-gaap:PrivatePlacementMember 2025-08-25 2025-08-25 0001527613 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-08-25 2025-08-25 0001527613 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-09-02 2025-09-02 0001527613 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-10-29 2025-10-29 0001527613 2024-04-27 0001527613 us-gaap:WarrantMember 2025-01-16 2025-01-16 0001527613 us-gaap:WarrantMember 2025-01-17 2025-01-17 0001527613 2025-01-16 0001527613 2025-01-17 0001527613 2025-12-02 2025-12-02 0001527613 2024-10-03 2024-10-03 0001527613 IMG:ExDirectorsMember 2025-08-22 2025-08-22 0001527613 us-gaap:InvestorMember IMG:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-04-10 2026-04-10 0001527613 us-gaap:InvestorMember IMG:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-04-10 0001527613 IMG:PrimaryOfferingProspectusMember us-gaap:SubsequentEventMember 2026-04-28 2026-04-28 0001527613 IMG:PrimaryOfferingProspectusMember us-gaap:SubsequentEventMember 2026-04-28 0001527613 IMG:ResaleProspectusMember us-gaap:SubsequentEventMember 2026-04-28 2026-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft iso4217:CNY IMG:Integer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December~~March 31, ~~2025~~2026

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 001-39338

CIMG Inc.

(Exact name of registrant as specified in its charter)

Nevada

38-3849791

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

Room R2, FTY D, 16/F, Kin Ga Industrial Building,

9 San On Street, Tuen Mun, Hong Kong00000

(Address of principal executive offices)

+ 852 70106695

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		IMG		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~March~~May 56, 2026, there were 1589,~~483~~971,~~547~~443 shares of the registrant’s Common Stock outstanding.

CIMG INC.

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~DECEMBER~~MARCH 31, ~~2025~~2026

PART I.	FINANCIAL INFORMATION	3
Item 1.	Financial Statements	3
	Consolidated Balance Sheets (unaudited)	3
	Consolidated Statements of Operations (unaudited)	4
	Consolidated Statements of Comprehensive Income Loss (unaudited)	5
	Consolidated Statements of Changes in Stockholders’ Equity (unaudited)	6
	Consolidated Statements of Cash Flows (unaudited)	7
	Notes to Consolidated Financial Statements (unaudited)	8
Item 2.	~~Quantitative~~Management’s Discussion and ~~Qualitative~~Analysis ~~Disclosures~~of ~~About~~Financial ~~Market~~Condition ~~Risk~~and Results of Operations	3029
Item 3.	~~Controls~~Quantitative and ~~Procedures~~Qualitative Disclosures About Market Risk	3034
PART II.	OTHER INFORMATION	31
Item 4.	Controls and Procedures	34
Item 1.	Legal Proceedings	31
PART II.	OTHER INFORMATION	35
Item 1A.	Risk Factors	31
Item 1.	Legal Proceedings	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 1A.	Risk Factors	35
Item 3.	Defaults Upon Senior Securities	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 4.	Mine Safety Disclosures	31
Item 3.	Defaults Upon Senior Securities	35
Item 5.	Other Information	31
Item 4.	Mine Safety Disclosures	35
Item 6.	Exhibits	31
Item 5.	Other Information	35
	SIGNATURES	33
Item 6.	Exhibits	36
	SIGNATURES	38

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements, including, without limitation, in the sections captioned “Risk Factors” and elsewhere. Any and all statements contained in this Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “target,” “seek,” “estimate,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future” and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Report may include, without limitation, statements regarding:

● our plans to obtain funding for our operations, including the funds required for technological development, product production, and product commercialization, as well as the funds necessary to ensure our continuous operation; ● our expectation that our existing capital resources will be sufficient to fund our operations for at least the next twelve months and our expectation to need additional capital to fund our planned operations beyond that; ● the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; ● our expectations regarding the effects of the suspension of trading of our ~~ability~~common tostock ~~maintain~~on ~~compliance~~Nasdaq, ~~with~~our quotation on the ~~listing~~OTC ~~requirements~~market, ofand ~~the~~any appeal or further review of Nasdaq’s ~~Capital~~delisting ~~Market~~determination; ● the impact to our business, including any supply chain interruptions, resulting from changes in general economic, business and political conditions, including changes in the financial markets and macroeconomic conditions resulting from a pandemic; ● the market size and growth trend of our products; ● our ability to compete with those companies that sell similar products or offer similar services; ● our ability to successfully achieve the anticipated results of strategic transactions; ● our expectations for future sales performance; ● our reliance on raw material suppliers or product manufacturers is to enable us to better produce our products and offer a wider variety of products to our customers.; ● regulatory developments in the U.S. and other countries; ● our ability to retain key management, sales, and marketing personnel;

●	the scope of protection we are able to establish and maintain for intellectual property rights covering our products and technology;

●	our ability to develop and maintain our corporate infrastructure, including our internal control over financial reporting;

●	the outcome of pending, threatened, or future litigation;

●	our financial performance; and

●	our use of the net proceeds from our recent offerings.

The forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon our current projections, plans, objectives, beliefs, expectations, estimates, and assumptions and are subject to a number of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Any forward-looking statements in this Report reflect our current views with respect to future events or our future financial performance and involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may influence or contribute to the inaccuracy of the forward-looking statements, or cause actual results to differ materially from current expectations, include, among other things, those listed under “Item 1A—Risk Factors” in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 13, 2026, and in our other reports filed with the SEC. Given these uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update the forward-looking statements contained in this Report to reflect any new information or future events or circumstances, or otherwise, except as required by law.

Item 1. Financial Statements

CIMG Inc.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	December 31,			September 30,
	March 31,			September 30,
	2025			2025
	2026			2025
ASSETS
Current assets:
Cash and cash equivalent	$	4517,~~356~~025		$	137,287
Accounts receivable, net		1,~~385~~387,~~960~~947			55,258
Inventories, net		~~157~~-			11,893,318
Prepaid expenses and other current assets		1,~~850~~735,~~651~~921			4,948,022
Other Receivables - Related Parties		~~208~~175,~~714~~536			92,457
Total current assets		3,~~490~~316,~~838~~429			17,126,342
Non-current assets:
Property and equipment, net		1,~~988~~150			2,200
Right-of-use asset - operating lease		1217,~~927~~801			20,340
Intangible assets, net		~~1,396~~-			2,201
Digital assets		6349,~~978~~847,~~821~~670			57,024,465
Total non-current assets		6349,~~995~~866,~~132~~621			57,049,206
Total assets	$	6753,~~485~~183,~~970~~050		$	74,175,548
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	2,~~864~~911,~~751~~873		$	1,464,144
Short term loan		~~452,764~~-			447,164
Current portion of lease liability - operating lease		67,~~445~~122			13,346
Convertible note-related party		-1,614,729			1,838,041
Other payables-related party		612,939			211,475
Convertible note		1,614,729			1,838,041
Advance Received		780,649			105,653
Other payables-related party		1,968,668			211,475
Other current liabilities		3,941,470			22,250,590
Advance Received		51,458			105,653
Tax payable		2,394,591			1,314,686
Other current liabilities		3,108,336			22,250,590
Total current liabilities		11,053,609			27,645,099
Tax payable		2,432,118			1,314,686
Total liabilities	$	11,051,607		$	27,645,099
Total current liabilities		12,094,304			27,645,099
Total liabilities	$	12,094,304		$	27,645,099
Stockholders’ equity:
15,483,382 and 9,825,704 shares of Common Stock issued and outstanding as of December 31, 2025 and September 30, 2025, respectively*		156			99
89,971,288 and 9,825,704 shares of Common Stock issued and outstanding as of March 31, 2026 and September 30, 2025, respectively*		901			99
Additional paid-in capital		161,~~961~~960,~~688~~943			132,531,653
Accumulated deficit		(~~106~~122,~~705~~095,~~592~~236	)		(87,228,118	)
Accumulated other comprehensive income		~~416~~403,~~217~~981			431,598
Total shareholders’ equity of the Company		5540,~~672~~270,~~469~~589			45,735,232
Non-controlling interests		~~759~~818,~~892~~157			795,217
Total stockholders’ equity		5641,~~432~~088,~~361~~746			46,530,449
Total liabilities and stockholders’ equity	$	6753,~~485~~183,~~970~~050		$	74,175,548

* On December 5, 2025, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of ~~Common~~common ~~Stock~~stock, par value $0.00001 per share. ~~The~~As a result of the Reverse Stock Split, ~~has reduced~~ the number of issued and outstanding shares of ~~Common~~the ~~Stock~~Company’s ascommon ofstock ~~September~~was ~~30,~~reduced ~~2025~~ from 196,514,084 shares to approximately 9,825,704 shares, ~~and~~retroactively ~~corresponding~~adjusted ~~retroactive~~for ~~adjustments have been made to~~ all ~~the~~periods ~~data for the listed period~~presented.

The accompanying notes are an integral part of these consolidated financial statements.

CIMG Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended			Three Months Ended
	Three Months Ended March 31, 2026			Three Months Ended March 31, 2025			Six Months Ended March 31, 2026			Six Months Ended March 31, 2025
	December 31, 2025			December 31, 2024
Revenues, net	$	3,214,991		$	-		$	18,983,787		$	22,853
Revenues, net	$	15,768,796		$	22,853
Cost of sales		(3,201,338	)		-			(18,882,718	)		(7,374	)
Cost of sales		(15,679,685	)		(7,374	)
Gross profit		13,653			-			101,069			15,479
Gross profit		89,111			15,479
Operating expenses		(1,337,791	)		(752,677	)		(3,417,780	)		(2,270,435	)
Operating expenses		(2,046,352	)		(1,517,758	)
Loss from operations		(1,324,138	)		(752,677	)		(3,316,711	)		(2,254,956	)
Loss from operations		(1,957,241	)		(1,502,279	)
Fair value variation		(14,131,150	)		-			(31,633,746	)		-
Fair value variation		(17,502,596	)		-
Other income		944			394,588			77,046			403,635
Other income		74,115			9,047
Loss from equity method investment					-						-
Loss from equity method investment		-			-
Other expense		(117	)		(7,303	)		(7,323	)		(50,320	)
Other expense		(125,150	)		(43,017	)
Gain on disposal of subsidiary		19,824			-			19,824			-
Interest expense, net		-			-
Loss on acquisition		-			(20,164	)		-			(20,164	)
Net loss from continuing operations		(19,510,872	)		(1,536,249	)
Interest expense, net		-			-			-			-
Income Tax		-			-
Net loss from continuing operations		(15,434,637	)		(385,556	)		(34,860,910	)		(1,921,805	)
Net loss	$	(19,510,872	)		(1,536,249	)
Income Tax		-			-			-			-
Non-controlling interest		(33,398	)		-
Net loss	$	(15,434,637	)	$	(385,556	)	$	(34,860,910	)	$	(1,921,805	)
Net loss attributable to CIMG Inc.		(19,477,474	)		(1,536,249	)
Non-controlling interest		(11,211	)		-			6,208			-
Basic and diluted loss per common share		(1.43	)		(0.17	)
Net loss attributable to CIMG Inc.		(15,423,426	)		(385,556	)		(34,867,118	)		(1,921,805	)
Basic and diluted weighted average number of Common Stock outstanding		13,601,997			8,982,676
Basic and diluted loss per common share		(0.49	)		(0.57	)		(1.56	)		(3.42	)
Basic and diluted weighted average number of Common Stock outstanding		31,385,302			677,517			22,356,669			562,071

The accompanying notes are an integral part of these consolidated financial statements.

CIMG Inc.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	Three Months Ended			Three Months Ended
	December 31, 2025			December 31, 2024
	March 31, 2026			March 31, 2025
Net loss attributable to CIMG Inc.	$	(1915,~~477~~423,~~474~~426	)	$	(1385,~~536,249~~556	)
Foreign currency translation to CIMG Inc.		(1513,~~381~~181	)		(~~192~~62,~~038~~517	)
Total other comprehensive income net of tax to CIMG Inc.		(1513,~~381~~181	)		(~~192~~62,~~038~~517	)
Comprehensive loss to CIMG Inc.	$	(1915,~~492~~436,~~855~~607	)	$	(1448,~~728,287~~073	)

	Six Months Ended			Six Months Ended
	March 31, 2026			March 31, 2025
Net loss attributable to CIMG Inc.	$	(34,867,118	)	$	(1,921,805	)

Foreign currency translation to CIMG Inc.		(28,703	)		(254,555	)
Total other comprehensive income net of tax to CIMG Inc.		(28,703	)		(254,555	)
Comprehensive loss to CIMG Inc.	$	(34,895,821	)	$	(2,176,360	)

The accompanying notes are an integral part of these consolidated financial statements.

CIMG Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

	Shares*		Amount		capital				deficit			income			interests			Total
	Common Stock				Additional paid-in				Accumulated			Accumulated Other Comprehensive			Non-controlling
	Shares*		Amount		capital				deficit			income			interests			Total
Balance September 30, 2025		9,825,704	$	99	$	132,531,653		-	$	(87,228,118	)	$	431,598		$	795,217		$	46,530,449
Common Stock issued for cash		416,667		4		1,999,996				-			-			-			2,000,000
Common Stock compensation		363,970		4		1,163,972				-			-			-			1,163,976
Issued private placement		3,595,000		36		16,177,464				-			-			-			16,177,500
Issued warrants		1,282,051		13		10,088,603				-			-			-			10,088,616
Other comprehensive income		-		-		-				-			(15,~~381~~522	)		(1,~~927~~566	)		(17,~~308~~088	)
Net loss		-		-		-		-		(19,~~477~~443,~~474~~692	)		-			~~(33~~17,~~398~~419	)		(19,~~510~~426,~~872~~273	)
Balance December 31, 2025		15,483,392	$	156	$	161,961,688		-	$	(106,~~705~~671,~~592~~810	)	$	416,~~217~~076		$	~~759~~811,~~892~~070		$	56,~~432~~517,~~361~~180
Restricted stock award		74,487,896		745		(745	)			-			-			-			-
Disposal of subsidiary		-		-		-				-			1,086			20,123			21,209
Other comprehensive income		-		-		-				-			(13,181	)		(1,825	)		(15,006	)
Net loss		-		-		-		-		(15,423,426	)					(11,211	)		(15,434,637	)
Balance March 31, 2026		89,971,288	$	901	$	161,960,943		-	$	(122,095,236	)	$	403,981		$	818,157		$	41,088,746

	Common Stock				Additional paid-in		Accumulated			Accumulated Other Comprehensive
	Shares		Amount		capital		receivable			deficit			income			interests			Total
	Shares*		Amount		capital		deficit			income			Total
	Common Stock				Additional paid-in		Subscription			Accumulated			Accumulated Other Comprehensive			Non-controlling
Balance September 30, 2024		248,912	$	2	$	81,260,653	$	(82,344,722	)	$	433,399		$	(650,668	)
	Shares		Amount		capital		receivable			deficit			income			interests			Total
Common Stock issued for cash		69,841		1		1,382,843		-			-			1,382,844
Balance September 30, 2024		248,912	$	2	$	81,260,653		-		$	(82,344,722	)	$	433,399			-		$	(650,668	)
Common Stock compensation		40,000		1		523,679		-			-			523,680
Common Stock issued for cash		69,841		1		1,382,843		-			-			-			-			1,382,844
Issued private placement		175,438		2		1,999,998		-			-			2,000,000
Common stock compensation		40,000		0		523,680		-			-			-			-			523,680
Issued warrants		2,799		1		-		-			-			1
Issued private placement		175,438		2		1,999,998		-			-			-			-			2,000,000
Other comprehensive income		-		-		-		-			(192,038	)		(192,038	)
Issued warrants		2,799		-		1		-			-			-			-			1
Net loss		-		-		-		(1,536,249	)		-			(1,536,249	)
Other comprehensive loss		-		-		-		-			-			(192,038	)		-			(192,038	)
Balance December 31, 2024		536,990	$	6	$	85,167,173	$	(83,880,971	)	$	241,361		$	1,527,570
Net loss		-		-		-		-			(1,536,249	)		-			-			(1,536,249	)
Balance December 31, 2024		536,990	$	5	$	85,167,175		-		$	(83,880,971	)	$	241,361			-		$	1,527,570
Common Stock issued for cash		972,881		10		9,999,990		(438,701	)		-			-			-			9,561,299
Other comprehensive loss		-		-		-		-			-			(62,517	)		-			(62,517	)
Net loss		-		-		-		-			(385,556	)		-			-			(385,556	)
Non-controlling interests		-		-		-		-			-			-			(19,374	)		(19,374	)
Balance March 31, 2025		1,509,871		15		95,167,165		(438,701	)		(84,266,527	)		178,844			(19,374	)		10,621,422

* ~~Corresponding~~Retroactively ~~retroactive~~adjusted ~~adjustments have been made~~ to ~~all the data for the listed period to~~ reflect the Reverse Stock Split.

The accompanying notes are an integral part of these consolidated financial statements.

CIMG Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three Months Ended			Three Months Ended
	Six Months Ended			Six Months Ended
	December 31, 2025			December 31, 2024
	March 31, 2026			March 31, 2025
Operating activities:
Net loss	$	(1934,~~510~~860,~~872~~910	)	$	(1,~~536~~921,~~249~~805	)
Adjustments to reconcile net loss to net cash used in operating activities:
Fair value variation		1731,~~502~~633,~~596~~746			-
Depreciation and amortization		1,017			7,771
Gain on disposal of subsidiary		(19,824	)		-
Noncash lease expense		7,413			41,349
Depreciation and amortization		3,346			15,444
Noncash lease expense		22,266			83,300
Common Stock compensation		1,163,976			523,680
Loss on acquisition		-			20,164
Bad debt losses		1,891			-
Change in operating assets and liabilities:
Accounts receivable		(1,~~330~~334,~~702~~580	)		-(71,034	)
Inventories		11,893,~~161~~318			(608,~~272~~147,696	)
Prepaid expenses and other current assets		3,~~097~~212,~~370~~101			91206,~~487~~027
Other receivables - related party		(~~116~~83,~~257~~079	)		-
Digital assets		(24,456,951	)		-
Accounts payable		1,~~400~~447,~~607~~730			(~~420~~783,~~136~~038	)
Other payables-related party		~~401~~1,~~464~~757,193			-
Accrued Interest		525,~~600~~929			-
Lease liability - operating lease		(627,~~901~~196	)		(4286,~~659~~388	)
Accrued expenses and other current liabilities		1(562,~~420,781~~381	)		56(132,~~248~~988	)
Net cash used in operating activities		(810,~~527~~129,~~698~~033	)		(110,~~338~~294,~~781~~334	)
Investing activities:
Proceeds from disposal of equipment		-			10,736
Cash received from the acquisition of subsidiaries		-			2,031
Cash decrease from disposal of subsidiary		(160	)		-
Net cash used in investing activities		(160	)		12,767
Financing activities:
Repayment from loans		-			(1,486,~~996~~995	)
Proceeds from issuance of convertible notes		-1,600,000			~~678,308~~-
Proceeds from issuance of Common Stock, exercise of stock options		8,453,075			2,000,000
Proceeds from private placement		-			2,000,000
Net cash provided by financing activities		8,453,075			1,191,312
Proceeds from issuance of Common Stock, exercise of stock options		8,453,075			9,561,299
Effect of foreign exchange on cash		(17,308	)		(192,038	)
Net cash provided by financing activities		10,053,075			10,074,304
Net change in cash		(91,931	)		(339,507	)
Effect of foreign exchange on cash		(44,144	)		(254,555	)
Net change in cash		(120,262	)		(461,818	)
Cash, beginning of period		137,287			464,222
Cash, end of period	$	4517,~~356~~025			~~124~~2,~~715~~404
Supplemental disclosure of cash flow information:
Cash paid for interest		-		$	-
Cash paid for taxes		-		$	-
Noncash investing and financing activities:
Deferred Stock Offering cost accrued ROU assets and liabilities added during the period	$	-			32,092

The accompanying notes are an integral part of these consolidated financial statements.

CIMG Inc.

Notes to Consolidated Financial Statements (unaudited)

~~December~~March 31, ~~2025~~2026

1. ORGANIZATION

CIMG Inc. (the “Company”) is incorporated in the State of Nevada. ~~and~~The ~~has~~Company’s ~~been~~Common Stock ~~listed~~commenced trading on the Nasdaq ~~Stock~~Capital Market ~~since~~in June 2020 under the symbol “NUZE. ” The Company was formerly known as ~~Nuzee~~NuZee, Inc., with the ticker symbol “NUZE”, and changed its corporate name ~~and ticker symbol~~ to “CIMG Inc.” and its ticker symbol to “IMG”, ~~respectively,~~ in October 2024. Following Nasdaq’s delisting determination in March 2026, trading of the Company’s Common Stock on Nasdaq was suspended, and the Company’s Common Stock is currently quoted on the OTC Markets under the ticker symbol “CIMG.”

The Company previously focused on specialty coffee products and related technologies. It is currently expanding its sales and distribution channels in Asia to encompass a broader range of consumer food and beverage products, supported by its online sales platform that incorporates a natural language search function.

CIMG Inc., its Hong Kong subsidiary DZR Tech Limited (“DZR Tech”), and its U.S. subsidiary Wewin Technology LLC (“Wewin”) may transfer cash to the Company’s PRC subsidiaries through capital contributions and intercompany loans, subject to applicable regulatory requirements.

On January 13, 2025, the Company established a wholly owned subsidiary in Singapore, CIMG PTE. LTD. (“Singapore CIMG”).

On March 10, 2025, Zhongyan Shangyue Technology Co., Ltd. (“Beijing Zhongyan”), a wholly owned subsidiary of the Company, acquired 51% of the equity interests in Shanghai Huomao Cultural Development Co., Ltd. (“Shanghai Huomao”). Shanghai Huomao holds 90% of the equity interests in Guizhou Zhutai Huomao Liquor Industry Co., Ltd. (“Zhutai”).

On March 21, 2025, Beijing Zhongyan established a wholly owned subsidiary, Henan Zhongyan Shangyue Technology Co., Ltd. (“Henan Zhongyan”).

On March 27, 2025, Beijing Zhongyan entered into a ~~business~~Business ~~cooperation~~Cooperation ~~intent~~Intent ~~agreement~~Agreement (the “Agreement”) with Xilin Online (Beijing) E-commerce Co., Ltd. (“Beijing Xilin”),. ~~pursuant~~Pursuant to ~~which~~the Agreement, certain shareholders of Beijing Xilin ~~intended~~ intend to transfer an aggregate of 51% of their equity ~~interests~~interest in Beijing Xilin to Beijing Zhongyan. ~~The~~On ~~Company~~March ~~completed~~31, 2025, the Company completed its acquisition of Beijing Xilin, onalong with the necessary business registration updates in China. On March 3111, ~~2025~~2026, ~~following~~the ~~completion~~Company entered ofinto a termination agreement with the ~~required~~original ~~business~~shareholders ~~registration~~of ~~procedures~~Beijing Xilin, pursuant to which the Company’s 51% equity interest in ~~China~~Beijing Xilin was transferred back to the original shareholders at no consideration, effective upon the termination of the original investment agreement.

On April 22, 2025, the Company completed the acquisition of Shanghai Huomao, together with the related business registration updates.

On August 1, 2025, Beijing Zhongyan entered into a business cooperation intent agreement with Shenzhen Zhimeng Qiyang Technology Co., Ltd. (“Zhimeng”), pursuant to which certain shareholders of Zhimeng agreed to transfer an aggregate of 51% of their equity interests to Beijing Zhongyan. The transfer was completed on August 1, 2025, and the related business registration change was approved on September 29, 2025.

On September 3, 2025, Beijing Zhongyan established a wholly owned subsidiary, Beijing Zhongyan Shangyue Holdings Co., Ltd. (“Beijing Shangyue”).

On September 16, 2025, Henan Zhongyan established a wholly owned subsidiary, Henan Nuanyou Agricultural Science and Technology Co., Ltd (“Nuanyou”)..

On September 23, 2025, DZR Tech Limited acquired Braincon Limited (“Braincon HK”) and its subsidiary, Beijing Xin Miao Shi Dai Technology Development Co., Ltd. (“Beijing Xinmiao”). DZR Tech Limited holds 100% of the equity interests in Braincon Limited.

On December 8, 2025, Beijing Zhongyan established a wholly owned subsidiary, Shenzhen Zhixi Yunjie Technology Co., Ltd. (“Zhixi Yunjie”).

On February 4, 2026, Beijing Xinmiao established a wholly-owned subsidiary, Foshan Dingyue Technology Co., Ltd (“Dingyue”).

On February 5, 2026, Beijing Zhongyan established a wholly-owned subsidiary, Foshan Lintai Technology Co., Ltd (“Lintai”).

On March 12, 2026, the Company, through DZR Tech, completed its acquisition of 100% of the equity interests in Daren Business Technology Limited (“Daren”). As a result, Daren became a wholly owned subsidiary of DZR Tech and an indirect wholly owned subsidiary of the Company.

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION

The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“GAAP”) in all material respects and have been consistently applied in preparing the accompanying financial statements.

2.2 PRINCIPLES OF CONSOLIDATION

The Company’s consolidated financial statements include the financial statements of the Company and entities controlled by the Company and its subsidiaries.

A subsidiary is an entity in which the Company, directly or indirectly, controls more than one half of the voting powers; or has the power to appoint or remove the majority of the members of the board of directors; or to cast a majority of votes at the meeting of directors; or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.

All intercompany transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.

2.3 NON-CONTROLLING INTERESTS

For the Company’s non-whole-owned subsidiaries, a non-controlling interest is recognized to reflect the portion of equity that is not attributable, directly or indirectly, to the Company. Non-controlling interests are classified as a separate line item in the equity section of the Company’s consolidated balance sheets and have been separately disclosed in the Company’s consolidated statements of operations and comprehensive (loss)/income to distinguish the interests from that of the Company.

2.4 EARNINGS PER SHARE

Basic earnings per common share are calculated by dividing net income or loss attributable to common shareholders by the weighted-average number of shares of Common Stock outstanding during the period.

Diluted earnings per common share reflect the potential dilution that could occur if securities or other contracts to issue Common Stock, such as stock options, warrants, or equity awards, were exercised or vested and resulted in the issuance of Common Stock that would share in the earnings of the Company. Potentially dilutive securities are excluded from the calculation of diluted earnings per share when their effect would be anti-dilutive.

On December 5, 2025, the Company effected a 1-for-20 reverse stock split of its issued and outstanding shares of Common Stock, par value $0.00001 per share. All share and per-share amounts presented in the consolidated financial statements and accompanying notes have been retrospectively adjusted to reflect the Reverse Stock Split.

2.5 GOING CONCERN AND CAPITAL CONSIDERATIONS

The Company has incurred recurring losses and negative cash flows from operations since inception. As of ~~December~~March 31, ~~2025~~2026, the Company had cash of $4517,~~356~~025 and negative working capital of $78,~~562~~777,~~771~~875. The Company expects that it will need to raise additional capital immediately to continue funding its operations. There can be no assurance that such financing will be available on acceptable terms, or at all.

As of ~~December~~March 31, ~~2025~~2026, the Company held 730 Bitcoin with a carrying amount of $6349,~~978~~847,~~821~~670. While these digital assets may be monetized, ~~their~~ their value is subject to significant market volatility, and they do not represent committed or assured sources of financing.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Management’s plans to address these conditions include raising additional equity or debt financing and executing its revised business strategy. However, as of the issuance date of these consolidated financial statements, management’s plans have not alleviated the substantial doubt about the Company’s ability to continue as a going concern.

The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty.

2.6 USE OF ESTIMATES

In preparing these consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Areas where management uses subjective judgment include, but are not limited to valuation of inventories and inventory impairment, fair value measurements of digital assets, assessment of goodwill impairment, allowance for credit losses, recoverability of deferred tax assets, and the recognition and measurement of revenue. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.

2.7 FAIR VALUE MEASUREMENTS

The Company applies the fair value measurement guidance in ASC 820, Fair Value Measurements, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used in valuation techniques and requires disclosures of fair value measurements by hierarchy level.

The fair value hierarchy prioritizes quoted prices in active markets for identical assets or liabilities (Level 1) as the highest priority and unobservable inputs (Level 3) as the lowest priority. Valuation techniques used to measure fair value include the market approach, the income approach, and the cost approach.

The classification of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The three levels of the fair value hierarchy are as follows:

Level 1 — Quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 — Unobservable inputs that reflect the Company’s own assumptions.

The Company measures certain assets and liabilities at fair value on both a recurring and non-recurring basis, including digital assets and financial instruments with embedded features, when applicable. The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses, other payables, convertible notes and other current liabilities approximate their fair values due to the short-term maturities of these instruments.

2.8 CASH AND CASH EQUIVALENTS

The Company considers cash on hand and demand deposits to be cash. Highly liquid investments with original maturities of three months or less at the date of purchase are considered cash equivalents, provided such investments are readily convertible to known amounts of cash and are subject to insignificant risk of changes in value. The Company did not hold any cash equivalents as of ~~December~~March 31,2026 ~~2025~~ and September ~~2024~~30,2025.

2.9 ACCOUNTS RECEIVABLES, NET

Accounts receivables are recorded at invoiced amounts and are evaluated periodically for collectability. The Company estimates an allowance for credit losses based on historical loss experience, the creditworthiness of customers, known and inherent risks in the receivable portfolio, and current economic conditions. Accounts receivables are written off against the allowance for credit losses when they are deemed uncollectible.

2.10 INVENTORIES, NET

Inventories, consisting primarily of raw materials and finished goods held for production and sale, are stated at the lower of cost or net realizable value. Inventory cost is determined using the weighted-average cost method. The Company reviews inventory levels on a quarterly basis and records inventory valuation allowances or write-downs, as necessary, to reflect net realizable value based on factors such as inventory aging, historical and forecasted demand, and market conditions.

2.11 FOREIGN CURRENCY TRANSLATION

The financial position and results of operations of each of the Company’s foreign subsidiaries are measured using the foreign subsidiary’s local currency as the functional currency. Revenues and expenses of each such subsidiary have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of stockholders’ equity, unless there is a sale or complete liquidation of the underlying foreign investment.

Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.

2.12 REVENUE RECOGNITION

The Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.

The Company primarily generates revenue from the trading and sale of goods. Revenue from product revenue is recognized when the Company satisfies its performance obligation by transferring control of the goods to the customer, which generally occurs upon delivery, when title and risk of loss pass to the customer.

For its product trading activities, the Company acts as the principal, as it controls the goods prior to transfer to the customer, bears inventory risk, and has discretion in establishing pricing. Accordingly, product revenue is recognized on a gross basis.

For service arrangements, the Company evaluates whether it controls the services prior to transfer to the customer. When the Company is determined to be the principal, service revenue is also recognized on a gross basis.

2.13 RETURN AND EXCHANGE POLICY

All products are inspected and securely packaged prior to shipment to help ensure that customers receive products in satisfactory condition. Customers may return products if they are not satisfied, in which case the Company will provide an exchange or refund of the purchase price, net of shipping charges. Return policies for wholesale customers vary in accordance with the terms of their respective agreements.

Under certain customer agreements, the Company provides chargebacks, pursuant to which the Company reimburses customers for a portion of the costs incurred to advertise and promote the Company’s products. The Company estimates and accrues such chargebacks based on contractual terms and historical experience. Chargebacks and returns, when applicable, are recorded as reductions of revenue and reflected in net sales.

For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026 and ~~2024~~2025, the Company did not record any material sales allowances related to estimated product ~~returns~~ returns or chargebacks.

2.14 COST RECOGNITION

The Company is engaged in the trading of goods and the provision of related services, with its cost of revenue covering products under the Maca Product Series, the Homology of Medicine and Food Series, and the Computing Power Product Series.

For the Maca Product Series, which consists of plant-based products, the Company operates a trading model whereby it procures Maca raw materials and engages third-party processors for production. Costs recognized for this product series primarily include the purchase cost of Maca raw materials, packaging costs, freight and logistics costs, and other directly attributable processing-related expenses.

For the Homology of Medicine and Food Series, the Company operates as a trading intermediary, and the cost of revenue primarily comprises the procurement cost of finished goods purchased from third-party suppliers.

For the Computing Power Product Series, the Company provides technical services supported by the procurement of equipment and development services. The cost of revenue mainly consists of technical development service fees and equipment purchase costs incurred in connection with the delivery of such services.

2.15 PROPERTY AND EQUIPMENT, NET

Property and equipment are stated at cost and depreciated over their estimated useful lives, with accumulated depreciation and impairment losses recorded as reductions of carrying amounts. Depreciation is computed using the straight-line method over the following estimated useful lives:

	-	Office equipment: 3 years
	-	Machinery and other equipment: 5 years

2.16 LONG LIVED ASSETS

The Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicated that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and a current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances.

2.17 INTANGIBLE ASSETS

Intangible assets with finite useful lives that are acquired are carried at cost less accumulated amortization and accumulated impairment losses. Amortization expense is recognized on a straight-line basis over the estimated useful lives of the intangible assets. The estimated useful lives and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. The Company ~~have~~has finite useful life intangible assets related to acquired tradename and software.

2.18 DIGITAL ASSETS

The Company’s digital assets consist solely of Bitcoin. Digital assets are initially recorded at cost and subsequently remeasured at fair value in accordance with ASU 2023-08. Changes in fair value are recognized in earnings each reporting period.

The fair value of Bitcoin is determined using quoted prices in active markets on Binance, which the Company has determined to be its principal market. Fair value measurements of digital assets are classified within Level 1 of the fair value hierarchy. Changes in fair value are recognized in the consolidated statements of operations within “Fair value variation”

The Company applies the first-in, first-out (FIFO) method to determine the cost basis of digital assets disposed of, if any.

2.19 INCOME TAXES

In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

The Company also follows the guidance related to accounting for income tax uncertainties. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.

2.20 RELATED PARTIES

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

2.21 STOCK BASED COMPENSATION

We account for share-based awards issued to employees in accordance with Accounting Standards Codification (ASC) 718, “Compensation-Stock Compensation.” Accordingly, employee share-based payment compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period, which is normally the vesting period. Share-based compensation to directors is treated in the same manner as share-based compensation to employees, regardless of whether the directors are also employees. In June 2018, the FASB issued ASU 2018-07 which simplifies several aspects of the accounting for non-employee transactions by stipulating that the existing accounting guidance for share-based payments to employees (accounted for under ASC Topic 718, “Compensation-Stock Compensation”) will also apply to non-employee share-based transactions (accounted for under ASC Topic 505, “Equity”). The Company implemented ASU 2018-07 on October 1, 2019 and the impact of the implementation was not material to the financial statements.

During the ~~year~~six months ended March 31, 2026, the Company issued an aggregate of 50363,~~000~~970 shares of Common Stock under the ~~2024~~2025 Equity Incentive ~~Plan, consisting of 40,000~~ ~~shares issued on December 24, 2024 and 10,000 shares issued on April 22, 2025~~Plan. ~~These amounts reflect the impact of the 1-for-20 reverse stock split, under which 1,000,000 shares issued prior to the stock split were retroactively adjusted to 50,000 shares.~~

2.22 COMPREHENSIVE INCOME/LOSS

Comprehensive income/loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, all items that are required to be recognized under current accounting standards as components of comprehensive income/loss are required to be reported in a financial statement that is presented with the same prominence as other financial statements. The Company’s current component of other comprehensive income/loss pertains to foreign currency translation adjustments.

3. CONCENTRATION AND RISKS

3.1 FOREIGN CURRENCY EXCHANGE RATE RISK

The Company’s operating transactions are mainly denominated in RMB. RMB is not freely convertible into foreign currencies. The value of the RMB is subject to changes by the central government policies and to international economic and political developments. In the PRC, certain foreign exchange transactions are required by law to be transacted only through authorized financial institutions at exchange rates set by the People’s Bank of China (the “PBOC”). Remittances in currencies other than RMB by the Company in the PRC must be processed through PBOC or other PRC foreign exchange regulatory bodies which require certain supporting documents in order to effect the remittances. As of ~~December~~March 31, ~~2025~~2026 and ~~2024~~September 30, 2025, the Company’s cash and cash equivalents denominated in RMB were RMB ~~212~~ 74,~~146~~120 (approximately $3010,~~235~~722), and RMB ~~536~~576,318 (approximately $7380,950), respectively, accounting for 6662.6698% and 058.0696% of the Company’s total cash and cash equivalents.

3.2 CONCENTRATION OF CREDIT RISK

The Company’s credit risk arises primarily from cash and cash equivalents, accounts receivable, other receivables from related parties, and other receivables included in prepaid expenses and other current assets. The carrying amounts of these financial instruments represent the Company’s maximum exposure to credit risk.

As of ~~December~~March 31, ~~2025~~2026, 7078% of the Company’s cash and cash equivalents were held by major financial institutions located in China and Hong ~~Hongkong,~~Kong; the remaining 3022% was held by financial institutions located in the United States. The Company believes that these financial institutions located in China, ~~Hongkong~~Hong Kong, and the United States are of high credit quality. Accounts at each institution in the United ~~States~~ States are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000. As of ~~December~~March 31, ~~2025~~2026, the Company had no cash balances at financial institutions in the United States in excess of the Federal Deposit Insurance Corporation limit.

Accounts receivable and other receivables are generally unsecured and arise in the ordinary course of business. Credit risk associated with these balances is mitigated through customer credit evaluations, ongoing monitoring of outstanding receivable balances, and the recognition of an allowance for expected credit losses based on historical experience, current conditions, and reasonable and supportable forecasts.

3.3 CONCENTRATION OF CUSTOMERS AND SUPPLIERS

For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026 and ~~2024~~2025, revenue was primarily derived from major customers disclosed below.

~~Three~~SCHEDULE ~~months~~OF ~~ended~~REVENUE ~~December~~BY ~~31,~~MAJOR ~~2025:~~CUSTOMERS

Customer Name	Sales Amount		% of Total Revenue			Accounts Receivable Amount		% of Total Accounts Receivable
Customer ZNF	$	11,981,591		75.98	%		-		-
Customer ZHXY	$	1,176,519		7.46	%		-		-

Six months ended March 31, 2026:

Three months ended December 31, 2024:

Customer Name		Sales Amount				% of Total Revenue				Accounts Receivable Amount				% of Total Accounts Receivable
Customer ZNF		$	12,118,011				63.83	%			-				-

Six months ended March 31, 2025:

Customer Name		Sales Amount				% of Total Revenue				Accounts Receivable Amount				% of Total Accounts Receivable
Customer LXM		$	13,524				59	%		$	-				-

For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026 and ~~2024~~2025, inventory purchases, including purchases related to the Company’s trading of goods, were primarily made from the major suppliers disclosed below.

~~Three~~Six months ended ~~December~~March 31, ~~2025~~2026:

Supplier Name	Purchases Amount		% of Total Purchases
Supplier TTY	$	1,080,346		29.21	%
Supplier YKZS	$	1,169,649		17.30	%
Supplier ACJN		~~766~~1,~~343~~145,888		2016.7294	%
Supplier SCNY		397,944		10.76	%
Supplier TTY		1,092,646		16.16	%
Supplier YFHYL		382,027		10.33	%

~~Three~~Six months ended ~~December~~March 31, ~~2024~~2025:

Supplier Name		Purchases Amount				% of Total Purchases
Supplier YKYM		$	28,~~058~~311,~~300~~593				100	%

4. NOTES TO THE CONSOLIDATED IN FINANCIAL STATEMENTS

4.1 ACCOUNTS RECEIVABLE, NET

As of ~~December~~March 31, ~~2025~~2026, the Company had gross accounts receivable of $1,~~385~~387,~~960~~947 ,net of an allowance for credit losses of $82.

As of September 30, 2025, the Company’s accounts receivable totaled $55,258, net of an allowance for credit losses of $2,107.

	December 31, 2025		September 30, 2025
Accounts receivable	$	1,385,960	$	57,365
Less: allowance for credit losses		-		(2,107	)
Accounts receivable, net		1,385,960		55,258

SCHEDULE OF ACCOUNTS RECEIVABLES

	March 31, 2026			September 30, 2025
Accounts receivable	$	1,388,029		$	57,365
Less: allowance for credit losses		(82	)		(2,107	)
Accounts receivable, net		1,387,947			55,258

The movements in the allowance for credit losses are as follows:

	March 31, 2026			September 30, 2025
Balance at beginning of the year	$	(2,107	)	$	(3,450,141	)
Additions		(82	)		(2,098	)
Foreign currency translation		306			(9	)
Write-offs		1,801			3,450,141
Balance at end of the year		(82	)		(2,107	)

4.2 INVENTORIES, NET

Inventories, net consisted of the following:

	December 31, 2025		September 30, 2025
Raw materials	$	-	$	12,799,608
Finished goods		157		154
Total inventories, gross		157		12,799,762
Less: inventory write-down		-		(906,444	)
Inventories, net		157		11,893,318

SCHEDULE OF INVENTORY

	March 31, 2026		September 30, 2025
Raw materials	$	-	$	12,799,608
Finished goods		-		154
Total inventories, gross		-		12,799,762
Less: inventory write-down		-		(906,444	)
Inventories, net		-		11,893,318

The movements in the inventories write-down were as follows:

SCHEDULE OF MOVEMENTS IN INVENTORIES

	March 31, 2026			September 30, 2025
Balance at beginning of the year	$	(906,444	)	$	(815,498	)
Additions		-			(902,776	)
Foreign currency translation		203,695			(3,668	)
Write-offs		702,749			815,498
Balance at end of the year		-			(906,444	)

4.3 PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets as of ~~December~~March 31,2026 ~~2025~~ and September 30, 2025 were comprised of the following:

	December 31, 2025		September 30, 2025
Prepaid expenses	$	291,445	$	197,217
Prepaid tax(1)		1,286,205		-
Advances to suppliers(2)		1,458,569		-
Deferred equity issuance cost(3)		1,797,500		-
Other current assets		114,303		185,431
Total		4,948,022		382,648

(1)	Prepaid tax represents input value-added tax (“VAT”) paid in advance for which the related VAT invoices had not yet been received as of the reporting date. Subsequent to period end, the Company received a portion of the outstanding invoices, and management expects to obtain the remaining invoices within six months. Accordingly, management believes the prepaid tax balance is fully recoverable.
	March 31, 2026		September 30, 2025
(2)	Advances to suppliers totaled $1,458,569, of which $1,404,745 related to a prepayment made to Daren (Beijing) Biomedical Technology Co., Ltd. for the procurement of inventory pursuant to a purchase agreement entered into during the year. Subsequent to September 30, 2025, the purchase agreement was mutually terminated, and the supplier refunded the full prepayment amount of $1,404,745 to the Company in November 2025. As of the date of these financial statements, no amounts remained outstanding related to this advance.
Prepaid expenses	$	286,585	$	291,445
(3)	On July 1, 2025, the Company entered into a consulting agreement providing for total professional fees of $5.5 million in connection with the Company’s August 25, 2025 private placement financing of 500 bitcoins (aggregate consideration of $55,000,000). The consulting fee was payable in up to 220,000,000 shares of Common Stock. At the transaction date, the Company did not have sufficient authorized shares to issue the full 220,000,000 shares. Accordingly, 148,100,000 shares were issued on a pro-rate basis using the Company’s available authorized shares. The remaining 71,900,000 shares were subject to shareholder approval and an amendment to the Company’s Articles of Incorporation to increase the authorized share capital. As of September 30, 2025, $1,797,500 of the total $5.5 million consulting fee, representing the portion attributable to the 71,900,000 shares not yet issued and therefore had not been settled in equity. Accordingly, this amount was recorded as other current assets – deferred equity issuance costs.
VAT input tax to be deducted		76,766		-
Prepaid tax(1)		1,304,747		1,286,205
Advances to suppliers(2)		49,184		1,458,569
Deferred equity issuance cost		-		1,797,500
Other current assets		18,639		114,303
Total		1,735,921		4,948,022

(1)	Prepaid tax represents input value-added tax (“VAT”) paid in advance for which the related VAT invoices had not yet been received as of the reporting date. Subsequent to period end, the Company received a portion of the outstanding invoices, and management expects to obtain the remaining invoices within six months. Accordingly, management believes the prepaid tax balance is fully recoverable.

(2)	As of March 31, 2026, the total amount paid to suppliers was $335,769, of which $286,064 represented advances to Beijing Yingtian Huyu Technology Co., Ltd. The Company is currently evaluating the SaaS live-streaming system of Beijing Yingtian Huyu Technology Co., Ltd., and the implementation plan for any subsequent advances is expected to be determined in 2026.

4.4 PROPERTY AND EQUIPMENT, NET

Property and equipment consisted of the following as of ~~December~~March 31, ~~2025~~2026 and September 30, 2025:

	December 31, 2025			September 30, 2025
Machinery & Equipment	$	30,910		$	30,910
Vehicles		-			-
Gross property and equipment		30,910			30,910
Less: accumulated depreciation		(28,922	)		(28,710	)
Less: reclassification to assets held for sale		-			-
Less: disposal of property and equipment		-			-
Net property and equipment		1,988			2,200

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2026			September 30, 2025
Machinery & Equipment	$	18,300		$	30,910
Vehicles		-			-
Gross property and equipment		18,300			30,910
Less: accumulated depreciation		(17,150	)		(28,710	)
Less: reclassification to assets held for sale		-			-
Less: disposal of property and equipment		-			-
Net property and equipment		1,150			2,200

4.5 LEASES

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use (“ROU”) assets and lease liabilities for most lease arrangements. The Company adopted ASC 842 effective October 1, 2019.

The Company evaluates lease arrangements on a quarterly basis to determine whether such arrangements meet the definition of a lease and whether recognition of ROU assets and lease liabilities is required. The Company elected the short-term lease practical expedient for leases with a term of 12 months or less and no purchase option.

4.5.1 LEASES WITH ~~RECOGNISED~~RECOGNIZED ROU ASSETS AND LEASE LIABILITIES

Vista, California – Office and Manufacturing Space

In May 2022, the Company renewed its office and manufacturing space lease in Vista, California, extending the lease term through September 30, 2025 (the prior lease was scheduled to expire on January 31, 2023). The lease provides for a monthly base rent of $8,451, plus common area maintenance charges. In connection with the renewal, the Company also leased an additional 1,796 square feet at a monthly base rent of $2,514 through March 31, 2025.

Tuen Mun, Hong Kong – Office Space

The Company leases office space on San On Street, Tuen Mun, Hong Kong, under a lease term from December 18, 2024 to December 17, 2026, at a monthly rent of RMB 4,167 (approximately $~~594~~603). As this lease represents a continuation and renewal of an existing lease and the combined non-cancellable term exceeds 12 months, the Company recognized right-of-use asset and lease liabilities for the lease as a single arrangement.

~~Beijing~~Wuxi, China – Office Space

Effective ~~February~~March 2819, 2025, the Company entered into a lease for office space located at ~~Room~~83-102 ~~303~~and 83-103, ~~3rd Floor~~Xishuidongcheng, ~~Hongsheng~~Liangxi ~~Building~~District, ~~Beijing~~Wuxi, China. The lease requires ~~monthly~~annual rental payments of RMB 16100,~~425~~000 (approximately $214,~~301~~466) and expires on March 3118, ~~2026~~2027. AsBecause the lease term exceeds 12 months, the Company recognized a right-of-use asset and corresponding lease liabilities related to this lease as of ~~September 30~~March 31, ~~2025~~2026.

Delray Beach, Florida – Principal Office

Effective September 1, 2024, the Company entered into a lease for its principal office space located at 16097 Poppyseed Circle, Unit 1904, Delray Beach, Florida 33484, for a monthly rent of $3,500. The lease term extended through August 31, 2025, and the lease was not renewed upon expiration.

4.5.2 SHORT TERM LEASES AND LOW VALUE LEASES

Boca Raton, Florida – Office Space

Effective October 10, 2025, the Company entered into a lease for office space located at 9127 Long Lake Palm Drive, Boca Raton, Florida 33496, with monthly rental payments of $2,500 through October 11, 2026. Because the lease term is 12 months or less, the Company elected the short-term lease practical expedient and, accordingly, did not recognize a right-of-use asset or lease liability related to this lease.

Henan, China – Office Space

The Company leases office space in Henan, China, with annual lease payments of approximately RMB 98,280 (approximately $1314,~~804~~217), payable in monthly installments of RMB 8,190 (approximately $1,~~150~~185). The lease expires on August 14, 2026. Because the remaining lease term as of ~~September~~March 3031, ~~2025~~2026 was less than 12 months, the Company elected the short-term lease practical expedient and did not recognize a right-of-use asset or lease liability related to this lease.

~~As of December 31~~Henan, ~~2025, the Company’s operating leases had a weighted-average remaining lease term of one year and a weighted-average~~ ~~discount~~China ~~rate~~– ofWarehouse ~~3%. Other information related to the Company’s operating leases is as follows:~~Space

Right-of-Use Assets	Amount
ROU asset – September 30, 2025	$	20,340
ROU assets added during the year		-
Amortization during the period		(7,413	)
ROU asset – December 31, 2025	$	12,927

The Company leases warehouse space in Henan, China, with annual lease payments of approximately RMB 24,000 (approximately $3,472), payable in quarterly installments of RMB 6,000 (approximately $868). The lease expires on February 9, 2027.

Lease Liabilities	Amount
Lease liability – September 30, 2025	$	13,346
Lease liability added during the year		-
Reduction during the period		(6,901	)
Lease liability – December 31, 2025	$	6,445

Foshan, China – Office Space

Lease Liabilities by Maturity	Amount
Lease Liability – Short-Term	$	3,502
Lease Liability – Long-Term		7,101
Lease Liability – Total	$	10,603

The Company leases office space located at Room 904 (No.946), Building 3, No. 17 Jihua 6th Road, Zumiao Street, Chancheng District, Foshan, with a contractual lease term from January 20, 2026 to March 31, 2028, which includes a rent-free period from January 20, 2026 to January 31, 2026. The monthly rent is RMB 500 (approximately $72.33). As of June 30, 2026, the Company will not renew the lease upon expiration. Due to the low value of the underlying asset, the Company elected the low-value asset lease practical expedient and did not recognize a right-of-use asset or lease liability related to this lease. For six months ended March 31, 2026, the operating expenses recognized for the period amount to RMB 1,500 (approximately $217).

The Company leases office space located at Room 904 (No.947), Building ~~following~~3, ~~table~~No. ~~summarizes~~17 Jihua 6th Road, Zumiao Street, Chancheng District, Foshan, with a contractual lease term from January 20, 2026 to March 31, 2028, which includes a rent-free period from January 20, 2026 to January 31, 2026. The monthly rent is RMB 500 (approximately $72.33). As of June 30, 2026, the Company’s ~~operating~~will not renew the lease ~~cost~~upon expiration. Due to the low value of the underlying asset, ~~short~~the Company elected the low-~~term~~value asset lease ~~cost,~~practical expedient and ~~related~~did ~~cash~~not ~~flow~~recognize ~~information~~a ~~for~~right-of-use ~~the~~asset or lease liability related to this lease. For ~~year~~six months ended ~~December~~March 31, ~~2025:~~2026, the operating expenses recognized for the period amount to RMB 1,500 (approximately $217).

Operating lease expenses	$	7,413
Short-term lease expenses		3,502
Cash paid for amounts included in the measurement of lease liabilities		7,101
Lease amortization		7,413
Interest portion		108

As of March 31,2026, the Company’s operating leases had a weighted-average remaining lease term of one year and a weighted-average discount rate of 3%. Other information related to the Company’s operating leases is as follows:

Right-of-Use Assets	Amount
ROU asset – September 30, 2025	$	20,340
ROU assets added during the year		28,272
Amortization during the period		(30,811)
ROU asset – March 31,2026	$	17,801

Lease Liabilities	Amount
Lease liability – September 30, 2025	$	13,346
Lease liability added during the year		7,122
Reduction during the period		(13,346	)
Lease liability – March 31,2026	$	7,122

Lease Liabilities by Maturity	Amount
Lease Liability – Short-Term	$	7,122
Lease Liability – Long-Term		-
Lease Liability – Total	$	7,122

The following table summarizes the Company’s operating lease cost, short-term lease cost, and related cash flow information for the six months ended March 31,2026:

Operating lease expenses	$	30,811
Short-term lease expenses		7,976
Cash paid for amounts included in the measurement of lease liabilities		26,525
Lease amortization		30,811
Interest portion		654

4.6 INTANGIBLE ASSETS, NET

The following table summarizes the Company’s intangible assets as of ~~December~~March 31, ~~2025~~2026:

	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Software		33,016		(31,620	)		1,396
Total		33,016		(31,620	)		1,396

SCHEDULE OF INTANGIBLE ASSETS

		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trademarks	$	140,000	$	(140,000	)	$	-
Software		34,003		(34,003	)		-
Total		174,003		(174,003	)		-

The following table summarizes the Company’s intangible assets as of September 30, 2025:

	Gross Carrying Amount		~~Accumulated Amortization~~	Accumulated Amortization		Net Carrying Amount
Trademarks	$	140,000	$	(140,000)	)	$	-
Software		33,016		(30,815)	)		2,201
Total		173,016		(170,815)	)		2,201

The ~~software~~ ~~intangible~~trademarks ~~asset~~have ~~was~~been ~~recognized~~fully asamortized ausing ~~result~~the ofaccelerated ~~the~~amortization method ~~acquisition~~as of ~~Shenzhen~~September ~~Zhimeng~~30, 2025. Amortization expense for intangible assets with finite useful lives was $~~805~~2,267 and $8015,~~550~~000 for the ~~years~~six months ended ~~December~~March 31, ~~2025~~2026 and ~~September 30,~~ 2025, respectively.

4.7 DIGITAL ASSETS

The Company’s digital assets consist solely of Bitcoin. Digital assets are measured at fair value, with changes in fair value recognized in earnings for each reporting period. As of ~~December~~March 31, ~~2025~~2026, the ~~company~~Company held 730 bitcoins, with a total value of $6349,~~978~~847,~~821~~670.

The following table is a summary of the Company’s Bitcoin activities as of March 31, 2026:

SCHEDULE OF BITCOIN ACTIVITY

	Amount
Beginning balance as of September 30, 2025	$	57,024,465
Increase in digital assets - Bitcoin		24,456,951
Decrease in digital assets - Bitcoin		-
Net change in fair value		(31,633,746	)
Ending balance as of March 31,2026	$	49,847,670

4.8 ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of ~~December~~March 31, ~~2025~~2026 and September 30, 2025 were as follows:

	December 31, 2025		September 30, 2025
Accounts payable	$	1,788,527	$	429,322
Accrued expenses		1,076,224		1,034,822
Total		2,864,751		1,464,144

4.9 SHORT TERM LOANS

	March 31, 2026		September 30, 2025
Accounts payable	$	1,770,730	$	429,322
Accrued expenses		1,141,143		1,034,822
Total		2,911,873		1,464,144

AsAccounts ~~of December 31, 2025, the Company’s short-term loans totaled $452,764, consisting of the following:~~payable

~~(a)~~As ~~Loan~~of ~~due~~March to31, ~~Mr.~~2026, ~~Sooncha~~accounts ~~Kim~~payable totaled $1,770,730, comprising $353,256 of legacy payables incurred under previous management and $1,417,474 of payables arising from procurement activities.

AnAccrued amount of $348,926 relates to a loan from Mr. Sooncha Kim, which is currently subject to ongoing litigation between the Company and Mr. Sooncha Kim. Repayment of this amount has been suspended pending the resolution of the litigation, and the ultimate repayment terms and timing, if any, will be determined based on the outcome of such proceedings.expenses

~~(b)~~As ~~Loan~~of ~~due~~March 31, 2026, accrued expenses totaled $1,141,143, primarily comprising accrued expenses related to ~~Social~~Nuzee Esingle-~~Commerce~~serving ~~Co.~~coffee and DRIPKIT products of $756,620 ~~Ltd~~and employee compensation payable of $384,523.

AnThe ~~amount~~accrued ofexpenses ~~$103,838~~related ~~represents~~to aNuzee single-serving coffee and DRIPKIT products primarily represent legacy ~~liability~~expenses incurred under previous management. ~~This~~and ~~amount~~are istreated ~~contractually~~in ~~repayable~~a onmanner orconsistent ~~before June~~with ~~30,~~other ~~2026~~legacy accounts payable balances. AsThese ofamounts continue to be recognized as accrued expenses as management is in the ~~date~~process of ~~these~~reviewing ~~financial~~and ~~statements,~~resolving nothe ~~repayment~~related ~~has~~obligations ~~been~~in ~~made,~~the ordinary course of business, and ~~the~~such ~~balance~~balances ~~remains~~remained ~~outstanding~~payable as of March 31, 2026.

Subsequent to December 31, 2025, no repayments have been made in respect of the above short-term loans. The balance due to Mr. Kim continues to be subject to ongoing litigation.

4.109 CONVERTIBLE NOTES

As of ~~December~~March 31, ~~2025~~2026 and September 30, 2025, the Company had outstanding unconverted convertible notes of approximately $~~Nil~~1,614,729 and $1,838,041, respectively.

For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026, $1,838,041 worth of convertible notes were converted into share of the Company’s Common Stock.

(a) Non-related party convertible notes

	December 31, 2025		September 30, 2025
Beginning balance	$	-	$	1,063,624
Issuance of convertible notes		-		10,144,186
Fair value adjustment		-		-
Conversion to Common Stock		-		(11,207,810	)
Ending balance		-		-

SCHEDULE OF CONVERTIBLE NOTES

All non-related party convertible notes outstanding as of September 30, 2024 were fully converted into shares of the Company’s Common Stock on October 31, 2024.

	March 31, 2026		September 30, 2025
Beginning balance	$	-	$	1,063,624
Issuance of convertible notes		-		10,144,186
Fair value adjustment		-		-
Conversion to Common Stock		-		(11,207,810	)
Ending balance		-		-

All non-related party convertible notes outstanding as of March 31,2026 were fully converted into shares of the Company’s Common Stock on October 31, 2025.

(b) Related party convertible notes

	December 31, 2025			September 30, 2025
Beginning balance	$	1,838,041		$	319,220
Issuance of convertible notes		-			3,693,041
Fair value adjustment		-			-
Conversion to Common Stock		(1,838,041	)		(2,174,220	)
Ending balance		-			1,838,041

SCHEDULE OF CONVERTIBLE NOTES

	March 31, 2026			September 30, 2025
Beginning balance	$	1,838,041		$	319,220
Issuance of convertible notes		1,614,729			3,693,041
Fair value adjustment		-			-
Conversion to Common Stock		(1,838,041	)		(2,174,220	)
Ending balance		1,614,729			1,838,041

Key issuance and conversion events

~~(1)~~ August 20, 2024: – The Company issued convertible notes with an aggregate principal amount of $1,300,000, of which $1,000,000 was subscribed by non-related parties and $300,000 by a related party. As of September 30, 2024, the Company recorded a fair value adjustment of $82,844 related to these notes.

October 31, 2024: – All holders of the August 2024 convertible notes elected to convert their notes into an aggregate of 1,396,813 shares of of Common Stock. The shares were registered pursuant to the Company’s Form S-1 filed on November 29, 2024.

~~(2)~~ December 12, 2024: – The Company issued convertible notes with an aggregate principal amount of $10,000,000, of which $8,145,000 was subscribed by non-related parties and $1,855,000 by a related party.

February 1011, 2025: – The Company obtained shareholder approval for the issuance of shares underlying the notes and warrants.

March 18, 2025: – the investors submitted their respective conversion notices, upon which the Company issued 19,457,618 shares of ~~Common~~ Common Stock to the investors.

~~(3)~~ August 21, 2025: – The Company entered into a convertible bond purchase agreement with certain non-U.S. investors to issue convertible notes with an aggregate principal amount of $4,000,000, at a conversion price of $0.24 per ~~shares~~share, subject to adjustment in accordance with the Notes.

During the year ended September 30, 2025, the non-related parties notes with a carrying value of $1,999,962 were converted into 8,333,333 shares of Common Stock.

October 30, 2025: – The remaining related party notes of 8,333,333 shares were issued ~~subsequent~~on toOctober ~~year-end~~31, ~~and are disclosed as a subsequent event~~2025.

February 11, 2026: The Company entered into a convertible note and warrant purchase agreement with certain non-U.S. investors providing for the private placement of convertible promissory notes in the aggregate principal amount of $5,000,000 and warrants to purchase the Company’s shares of Common Stock in reliance on the registration exemptions of Regulation S. The Notes were issuable in two tranches, consisting of (i) an initial tranche in the aggregate principal amount of $1,600,000 and (ii) a second tranche in the aggregate principal amount of $3,400,000. The Notes bear interest at an annual rate of 7% and have a maturity date of August 12, 2027. On February 13, 2026, the Company completed the initial closing and issued Notes in the aggregate principal amount of $1,600,000 to these investors.

On March 21, 2026, in light of the Company’s delisting from The Nasdaq Stock Market LLC on March 6, 2026 and its current quotation on the OTC market, the Company entered into an Amended and Restated Convertible Note and Warrant Purchase Agreement with the investors, which amended and restated the February 11, 2026 purchase agreement. The parties acknowledged that only one closing occurred under the original agreement, namely the initial closing on February 13, 2026, and that no other closings shall occur. In connection with the amendment, the Company issued amendments to the original notes and amended and restated warrants to the investors. The amended notes provide that they are not convertible prior to stockholder approval and that the conversion price is subject to a floor price of $0.10 per share. The amended and restated warrants become exercisable only upon stockholder approval and may be exercised for cash only at an exercise price of $0.015 per share. The Company also agreed to file a registration statement on Form S-1 covering the resale of the shares issuable upon conversion of the amended notes and exercise of the amended and restated warrants.

The convertible notes were measured at fair value, with changes in fair value recognized in fair value variation in the consolidated statements of operations.

4.1110 OTHER CURRENT LIABILITIES

As of ~~December~~March 31, ~~2025~~2026 and September 30, 2025, other current liabilities amounted to $3,~~941~~108,~~470~~ 336 and $22,250,590, respectively.

Other current liabilities consisted of the following:

	December 31, 2025		September 30, 2025
Advances received for equity subscriptions(1)	$	159,657	$	18,134,657
Provision for liabilities related to directors’ litigation(2)		222,062		222,062
Professional service fees payable – Bitcoin transaction(3)		3,333,579		3,663,269
Others		226,172		230,602
Total		3,941,470		22,250,590

SCHEDULE OF OTHER CURRENT LIABILITIES

	March 31, 2026		September 30, 2025
Advances received for equity subscriptions⁽¹⁾	$	159,657	$	18,134,657
Provision for liabilities related to directors’ litigation⁽²⁾		222,062		222,062
Professional service fees payable – Bitcoin transaction⁽³⁾		2,089,798		3,663,269
Others		636,819		230,602
Total		3,108,336		22,250,590

(1)

Advances received for equity subscriptions

~~Advances~~Advance ~~received~~receipts for equity subscriptions ~~include~~are as follows: $~~159~~129,~~657~~662.80 ~~relating~~for to a share subscription by Mr. Sooncha Kim, ~~and~~ $1729,~~975,000~~994.20 ~~representing~~for a share subscription ~~funds~~by ~~received~~Mr. inKenji ~~connection with Bitcoin-related investments~~Hashimoto.

The issuance of shares relating to Mr. Kim’s equity subscription has been placed on hold due to ongoing litigation between Mr. Kim and the Company. Management intends to resolve the equity subscription upon conclusion of the legal proceedings.

With respect to the Bitcoin-related equity subscriptions, on September 25, 2025, the Company’s board of directors approved an increase in the authorized number of the Common Stock from 200,000,000 to 600,000,000 shares. In October 2025, the Company amended its Articles of Incorporation to effect the increase. Following the amendment, 71,900,000 shares were issued and recorded as outstanding in the Company’s shareholder register.

(2)

Provision for liabilities related to directors’ litigation

The provision for liabilities related to directors’ litigation of $222,062 represents management’s estimate of costs associated with ongoing legal proceedings involving certain directors as of ~~September~~March 3031, ~~2025~~2026.

(3)

Professional service fees payable – Bitcoin transaction

The professional service fees payable of $32,~~663~~089,~~269~~798 relate to a financial advisory services agreement executed on July 1, 2025, between the Company and Sunflower Tech Limited, in connection with a Bitcoin-related asset transaction with a total transaction value of $55.0 million. Under the agreement, the advisory fee is calculated at 10% of the transaction value, amounting to $5.5 million. As of ~~December~~March 31, ~~2025~~2026 and September 30, 2025, the remaining payable balances of the ~~company~~Company were $32,~~333~~089,~~579~~798 and $3,663,269 respectively.

4.1211 TAX PAYABLE

As of ~~December~~March 31, ~~2025~~2026 and September 30, 2025, taxes payable amounted to $2,~~394~~432,~~591~~118 and $1,314,686, respectively.

	December 31, 2025		September 30, 2025
VAT payable	$	2,391,483	$	1,311,578
Income tax payable		3,108		3,108
Total		2,394,591		1,314,686

SCHEDULE OF TAX PAYABLE

4.13 OPERATING EXPENSES

	March 31, 2026		September 30, 2025
Accrued sales taxes payable	$	2,430,633	$	1,311,578
Other tax payable		1,485		3,108
Total		2,432,118		1,314,686

~~For the three months ended December 31, 2025, the operating expenses were $2,046,352~~4. ~~This mainly included personnel costs of $1,271,874,~~12 ~~sales~~OPERATING and marketing expenses of $201,219, depreciation and amortization of $1,073, professional fees (including legal, audit, and consulting services) of $490,206, travel expenses of $27,294, office expenses of $33,890, and other operating expenses of $20,796.EXPENSES

For the ~~three~~six months ended ~~December~~March 31, ~~2024~~2026, the operating expenses were $13,~~517~~417,~~758~~780. This mainly included personnel costs of $~~617~~1,~~824~~347,033, sales and marketing expenses of $~~104~~88,~~403~~303, depreciation and amortization of $722,~~771~~920, professional ~~services~~fees ~~such~~(including aslegal, ~~lawyers~~audit, ~~auditors~~ and ~~consultants~~consulting services) of $~~642~~1,~~125~~766,863, travel expenses of $3585,~~084~~586, office expenses of $7371,~~585~~794, bad debt loss of 1,891 and other ~~expenses~~operating expenses of $3633,~~966~~390.

4For the six months ended March 31, 2025, the operating expenses were $2,270,435.14 This mainly includes personnel costs of $712,008, sales and ~~OTHER~~marketing ~~INCOME~~expenses of $46,152, depreciation and amortization of $100,924, professional services such as lawyers, auditors and consultants of $1,248,215, travel expenses of $72,947, office expenses of $52,480 and other expenses of $37,710.

~~For~~4.13 ~~the~~OTHER ~~three months ended December 31, 2025, other income was $74,115, primarily arising from the consulting services provided by the Company.~~INCOME

For the ~~three~~six months ended ~~December~~March 31, ~~2024~~2026, ~~the~~ other income was $977,~~047.~~046, ~~It is~~ mainly ~~because~~derived offrom ~~the write-off~~ other ~~payables~~business revenues.

~~4.15~~For ~~OTHER~~the ~~EXPENSES~~six months ended March 31, 2025, the other income was $403,635. It is mainly because of the settlement and forgiveness of account payable.

~~For~~4.14 ~~the~~OTHER ~~three months ended December 31, 2025, other expense was $125,150, primarily attributable to the cost expenditures corresponding to other income, the company’s financial expenses, and other factors.~~EXPENSES

For the ~~three~~six months ended ~~December~~March 31, ~~2024~~2026, other expense ~~totaled~~was $437,~~017~~323, primarily ~~included~~attributable ~~write~~to ~~off~~the ofcost ~~deferred~~expenditures ~~financing~~corresponding ~~costs~~to ~~and~~other ~~sublease~~income ~~expense~~and other factors.

For the six months ended March 31, 2025, other expense totaled $50,320, primarily included financing expense and other factors.

4.15 INCOME TAX

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. No asset or liability for unrecognized tax benefits was recorded as of March 31, 2026 or September 30, 2025.

United States

CIMG Inc. and Wewin are incorporated in the United States and are subject to U.S. federal corporate income tax at a statutory rate of 21%. For the six months ended March 31, 2026, these entities did not generate taxable income; accordingly, no provision for U.S. federal income tax was recorded.

Hong Kong

DZR Tech Limited is incorporated in Hong Kong and is subject to Hong Kong Profits Tax under the two-tiered profits tax rates regime, whereby the first HK$2 million of assessable profits are taxed at 8.25%, and profits in excess of HK$2 million are taxed at 16.5%. DZR Tech Limited did not generate taxable income for the six months ended March 31,2026, and therefore no provision for Hong Kong profits tax was recorded.

People’s Republic of China

Beijing Zhongyan, Henan Zhongyan, Nuanyou, Beijing Xinmiao, Zhimeng, Zhutai, Shanghai Huomao, Beijing Xilin, Foshan Lintai and Foshan Dingyue are incorporated in the People’s Republic of China and are subject to enterprise income tax at a statutory rate of 25%. For small and low-profit enterprises, taxable income is calculated at a reduced rate of 25%, and the corporate income tax policy is paid at a rate of 20%. All entities did not generate taxable income for the six months ended March 31, 2026, accordingly, no provision for PRC enterprise income tax was recognized.

Schedule of Income Tax Expense (Benefit)

SCHEDULE OF INCOME TAX EXPENSE BENEFIT

	Six months ended March 31, 2026
Current income tax expense	$	-
Deferred income tax expense		-
Total income tax expense		-

Reconciliation of Statutory Tax Benefit to Income Tax Expense		(34,880,734	)
Tax benefit at statutory U.S. federal rate (21%)	$	(7,326,257	)
Effect of different tax rates applicable to subsidiaries		28,831
Effect of unrecognized deductible temporary differences		(6,643,087	)
Effect of tax loss carryforwards		13,940,513
Income tax expense	$	-

5. GEOGRAPHIC CONCENTRATIONS

The Company is organized based on fundamentally three business segments although it does sell its products on a world-wide basis. The Company is organized in two geographical segments. The Company jointly produces and sells its products in North America and China. Information about the Company’s geographic operations for the ~~three~~six months ended ~~December~~March 31, ~~2025,~~2026 and ~~2024~~2025 are as follows:

~~Geographic Concentration~~SCHEDULE OF GEOGRAPHICAL OPERATIONS

Net Revenue:	Three months ended December 31, 2025		Three months ended December 31, 2024
North America	$	-	$	-
P.R.C		15,768,796		22,853
		15,768,796		22,853

Geographic Concentration:

Property and equipment, net:	Three months ended December 31, 2025		Three months ended December 31, 2024
Net Revenue:	Six months ended March 31, 2026		Six months ended March 31, 2025
North America	$	-	$	-
P.R.C.	$	18,983,787	$	22,853
P.R.C		1,988		1,997
		1,988		1,997

Property and equipment, net:

March 31,

2026

September 30,
2025

P.R.C.

1,150

2,200

6. SEGMENT INFORMATION

FASB ASC Topic 280, “Segment Reporting” (“ASC 280”) establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.

The Company’s CODM has been identified as the Chief Financial Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, Management derived reportable segments based on business lines.

As of ~~December~~March 31, ~~2025~~2026, the Company currently has the following reportable segments: Homology of Medicine and Food Series, Computing Power Product Series, Maca Product Series and others.

	Business Line									Others
	Homology of Medicine and Food			Computing Power Product			Maca Product			Unallocated Headquarter
	Series			Series			Series			Costs			Total
Revenues, net	$	1,426,832		$	2,360,373		$	11,981,591		$	-		$	15,768,796
Cost of revenue		(1,408,560	)		(2,289,534	)		(11,981,591	)		-			(15,679,685	)
Gross profit		18,272			70,839			-			-			89,111
Operating expenses		(122,596	)		(256,436	)		-			(1,667,320	)		(2,046,352	)
Loss from operations		(104,324	)		(185,597	)		-			(1,667,320	)		(1,957,241	)
Fair value variation		-			-			-			(17,502,596	)		(17,502,596	)
Other income		74,115			-			-			-			74,115
Other expense		(117,049	)		(245	)		-			(7,856	)		(125,150	)
Segment Loss	$	(147,258	)		(185,842	)		-			(19,177,772	)		(19,510,872	)

SCHEDULE OF SEGMENT INFORMATION

	Series			Series			Series			Costs			Total
	Six months ended March 31, 2026
	Business Line									Others
	Homology of Medicine and Food			Computing Power Product			Maca Product			Unallocated Headquarter
	Series			Series			Series			Costs			Total
Revenues, net	$	1,855,618		$	5,010,158		$	12,118,011		$	-		$	18,983,787
Cost of revenue		(1,830,086	)		(4,933,945	)		(12,118,589	)		(98	)		(18,882,718	)
Gross profit		25,532			76,213			(578	)		(98	)		101,069

Operating expenses		(47,537	)		(86,256	)		(270,238	)		(3,013,749	)		(3,417,780	)
Loss from operations		(22,005	)		(10,043	)		(270,816	)		(3,013,847	)		(3,316,711	)

Fair value variation		-			-			-			(31,633,746	)		(31,633,746	)
Gain on disposal of subsidiary		-			-			-			19,824			19,824
Other income		155			178			1,654			75,059			77,046
Other expense		(8	)		(13	)		(90	)		(7,212	)		(7,323	)
Segment Loss	$	(21,858	)		(9,878	)		(269,252	)		(34,559,922	)		(34,860,910	)

7. RELATED PARTY BALANCES AND TRANSACTIONS

As of ~~December~~March 31, ~~2025~~2026, the Company had the following major related party transactions:

SCHEDULE OF RELATED PARTY TRANSACTIONS

Name of related parties		Relationship with Company
Wanhai Liu		Shareholder of Xilin Online (Beijing) E-commerce Co., Ltd
Tianyong Lv		Manager of Xilin Online (Beijing) E-commerce Co., Ltd
Shengqing Li		Manager of Shenzhen Zhimeng Qiyang Technology Co., Ltd.
Hongfang Xie		Shareholder of Shanghai Huomao Cultural Development Co., Ltd.
Wenlong Tong		President of CIMG Inc.
Wenwen Yu		Director of Wewin Technology LLC
Yujie Liu		The shareholders of CIMG
Yanli Hou		Director of CIMG Inc.

(a) Significant transactions with related parties

Name of related parties	Related party transactions	~~December~~Six months ended March 31, ~~2025~~2026
Wanhai Liu	Loan advanced to Xilin Online (Beijing) E-commerce Co., Ltd	$	12,698
Shengqing Li	Loan advanced to Shenzhen Zhimeng Qiyang Technology Co., Ltd.	$	9,890
Tianyong Lv	Loan advanced to Xilin Online (Beijing) E-commerce Co., Ltd		12,940
Hongfang Xie	Loan advanced to Shanghai Huomao Cultural Development Co., Ltd.		9,043
Shengqing Li	Loan advanced to Shenzhen Zhimeng Qiyang Technology Co., Ltd.		191,329
Hongfang Xie	Loan advanced to Guizhou Zhutai Huomao Liquor Industry Co., Ltd.		4,593
Hongfang Xie	Loan advanced to Shanghai Huomao Cultural Development Co., Ltd.		5,037
Wenwen Yu	Loan advanced to CIMG Inc.		15,000
Hongfang Xie	Loan advanced to Guizhou Zhutai Huomao Liquor Industry Co., Ltd.		117,487
Wenlong Tong	Loan advanced from Zhongyan Shangyue Technology Co., Ltd		18,661
Yujie Liu	Loan advanced to Zhongyan Shangyue Technology Co., Ltd		213,198
Wenwen Yu	Loan advanced from Wewin Technology LLC.		(66,207	)
Yujie Liu	Loan advanced to Henan Zhongyan Shangyue Technology Co., Ltd		52,730
Wenwen Yu	Loan advanced to CIMG Inc		7,500
Wenlong Tong	Loan advanced from Zhongyan Shangyue Technology Co., Ltd		(15,911	)
Wenwen Yu	Loan advanced from Wewin Technology LLC.		(150,762	)
Yanli Hou	Loan advanced from Zhongyan Shangyue Technology Co., Ltd		(42,041	)

Nature of Related Party Transactions

As of ~~December~~March 31, ~~2025~~2026, the Company and its subsidiaries entered into certain transactions with related parties in the ordinary course of of business. These transactions primarily consisted of advances made by related parties to settle operating and administrative expenses on behalf of the Company’s subsidiaries, as well as financing arrangements entered into with related parties.

Except as otherwise disclosed, all advances from or to related parties were unsecured, non-interest bearing, and had no fixed repayment terms. Management believes that the terms of these transactions are not materially different from those that could have been obtained from independent third parties under similar circumstances.

(b) Balances with related parties

	December 31, 2025
	March 31, 2026
Wenlong Tong	$	15,911
Wenwen Yu	$	140,001
Wenwen Yu		150,762
Yanli Hou		35,535
Yanli Hou		42,041
Total amounts due from related parties		175,536
Total amounts due from related parties		208,714
Shengqing Li	$	195,656
Wanhai Liu	$	12,698
Hongfang Xie		14,329
Tianyong Lv		12,940
Wenwen Yu		15,000
Shengqing Li		191,329
Yujie Liu		99,385
Hongfang Xie		122,544
Dada Business Trading Co., Limited		651,103
Wenwen Yu		7,500
YY Tech Inc.		217,018
Yujie Liu		265,928
Wenlong Tong		149
Total amounts due to related parties		612,939
Yanli Hou		591
Xujia Liu		60,000
VMADE CO.,LIMITED		225,000
DYT INFO PTE. LTD.		220,000
RR Digital Tech Ltd.		37,000
Joyer investment Limited		233,437
Total amounts due to related parties		1,968,668

The amounts due from and due to related parties primarily arose from payments made on behalf of the Company or its subsidiaries for operating, administrative, and legal expenses, as well as advances and settlements in the ordinary course of business. Such balances are recorded at their original amounts, which approximate fair value due to their short-term nature.

As of the date of issuance of these financial statements, management does not expect any material credit losses in respect of amounts due from related parties.

8. ISSUANCE OF EQUITY SECURITIES

On December 5, 2025, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of Common Stock, par value $0.00001 per share. This reverse stock split has reduced the number of shares of Common Stock as of September 30, 2025 from 196,514,084 shares to 9,825,704 shares, and corresponding retroactive adjustments have been made to all the data for the listed period.

(1) For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026, the Common Stock issued for cash was as follows:

Date	Transaction type	Description	Shares issued		Cash/consideration ($)
August 21, 2025	Convertible Note Purchase Agreement (From 8-K filed August 26, 2025, Form 8-K filed on November 12, 2025)	On August 21, 2025, the Company entered into a $4,000,000 convertible bond purchase agreement with certain non-U.S. investors. The notes are convertible into shares of the Company’s Common Stock at a conversion price of $0.24 per share. On September 9, 2025, the Company issued 8,333,333 shares. On October 30, 2025, the Company issued the remaining 8,333,333 shares.		8,333,333	$	2,000,000
Total (Pre-Reverse Stock Split)				8,333,333		2,000,000
Total (Post-Reverse Stock Split)				416,667		13,382,030

SCHEDULE OF COMMON SHARES ISSUED

Date	Transaction type	Description	Shares issued		Cash/consideration ($)

August 21, 2025	Convertible Note Purchase Agreement (From 8-K filed August 26, 2025, Form 8-K filed on November 12, 2025)	On August 21, 2025, the Company entered into a $4,000,000 convertible bond purchase agreement with certain non-U.S. investors. The notes are convertible into shares of the Company’s Common Stock at a conversion price of $0.24 per share. On September 9, 2025, the Company issued 8,333,333 shares to these investors. On October 30, 2025, the Company issued the remaining 8,333,333 shares.		8,333,333	$	2,000,000
August 21, 2025	Convertible Note Purchase Agreement (From 8-K filed August 26, 2025, Form 8-K filed on November 12, 2025)	On August 21, 2025, the Company entered into a $4,000,000 convertible bond purchase agreement with certain non-U.S. investors. The notes are convertible into shares of the Company’s Common Stock at a conversion price of $0.24 per share. On September 9, 2025, the Company issued 8,333,333 shares to these investors. On October 30, 2025, the Company issued the remaining 8,333,333 shares to these investors.		8,333,333	$	2,000,000
		Total (Pre-Reverse Stock Split)		8,333,333		2,000,000
		Total (Post-Reverse Stock Split)		416,667		2,000,000

(2) For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026, the issuance of Common Stock due to the Common Stock compensation was as follows:

Date

Transaction type

Description

Shares issued

Cash/consideration ($)

November 21, 2025.

2025 Equity Incentive Plan (From S-8 filed November 21, 2025)

~~This~~Issued under the Company’s Registration Statement on Form S-8 ~~(this “Registration Statement”) is filed by CIMG Inc.~~, awhich ~~Nevada~~registers ~~corporation~~ (~~the “Registrant” or “Company”), to register (~~i) 7,279,400 shares of the ~~Registrant~~Company’s ~~shares of~~ Common Stock, ~~par value $0.00001 per share (the “Common Stock”),~~ issuable under the Company’s 2025 Equity Incentive Plan (the “2025 Plan”), and (ii) 38,000,000 shares of Common Stock, issuable under the ~~Registrant~~Company’s 2026 Equity Incentive Plan (the “2026 Plan”).

7,279,400

1,163,976

~~Total (Pre-Reverse Stock Split)~~

Total (Pre-Reverse Stock Split)

7,279,400

1,163,976

~~Total (Post-Reverse Stock Split)~~

Total (Post-Reverse Stock Split)

363,970

1,163,976

(3) For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026, the issuance of Common Stock due to the private placement was as follows:

Date

Transaction type

Description

Shares issued

Cash/consideration ($)

August 25, 2025*

Securities Purchase Agreement

(Form 8-K filed on August 27, 2025, Form 8-K/A filed on September 2, 2025)

On August 25, 2025, the Company entered into a securities purchase agreement with certain non-U.S. investors for total consideration of $55,000,000, payable in Bitcoin, at a purchase price of $0.25 per share. The agreement provides for the issuance of up to 220,000,000 shares of Common Stock through a private placement, of which 148,100,000 shares, representing $37,025,000 of consideration, were issued during the period.

On September 2, 2025, the Company issued 148,100,000 shares of Common Stock to certain non-U.S. investors.

On October 29, 2025, the Company issued the remaining 71,900,000 shares.

71,900,000

16,177,500

Total (Pre-Reverse Stock Split)

71,900,000

16,177,500

Total (Post-Reverse Stock Split)

3,595,000

16,177,500

Restricted Stock Awards

~~For~~On February 27, 2026, the ~~three~~Company ~~months~~entered ~~ended~~into ~~December~~an 31Amended and Restated Equity Transfer Agreement (the “A&R Equity Transfer Agreement”) with DZR Tech Limited, ~~2025~~a Hong Kong company and a wholly owned subsidiary of the Company (the “Purchaser”), Shelei Jiang, a Chinese individual (the “Seller”), and Daren Business Technology Limited, a company incorporated under the laws of the British Virgin Islands (the “Target”). The A&R Equity Transfer Agreement amended and restated in its entirety that certain Equity Transfer Agreement, dated February 11, 2026, by and between the Seller and the Purchaser. Pursuant to the A&R Equity Transfer Agreement, the Seller will sell to the Purchaser 100 ordinary shares of the Target, representing 100% of the issued and outstanding ordinary shares of the Target, for a purchase price of zero cash consideration (the “Acquisition”). On March 10, 2026, the Company and ~~did~~each of Dundas Technology Limited and Kellyview Investment Limited, each a Hong Kong company and a designee of the Seller pursuant to the terms of the A&R Equity Transfer Agreement, entered into a separate performance share issuance agreement, pursuant to which the Company shall issue to Dundas Technology Limited and Kellyview Investment Limited, on or before April 10, 2026, in the aggregate up to 74,487,896 shares of the Company’s Common Stock, par value $0.00001 per share (the “Award Shares”), with one-half of the Award Shares to be issued to Dundas Technology Limited and one-half to Kellyview Investment Limited, as a post-closing, performance-based equity award with respect to the Target. On March 12, 2026, the Company issued 37,243,948 shares of Common Stock to Dundas Technology Limited and 37,243,948 shares of Common Stock to Kellyview Investment Limited. Such shares will be subject to transfer restrictions and will be eligible for leak-out in installments only upon the achievement of specified audited revenue targets of the Target during performance periods beginning on April 1, 2026 and ending on September 30, 2029. The revenue targets are denominated in Renminbi and increase over successive performance periods. Any such shares that are not ~~grant~~eligible ~~any~~to ~~restricted~~leak ~~stock~~out ~~awards~~on or prior to the applicable deadline set forth in the performance share issuance agreements shall be forfeited and cancelled for no consideration.

Grants to Independent Directors

No restricted stock awards were granted to the Company’s independent board members during the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026.

Forfeiture of Restricted Shares

For the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026, no restricted stock awards were forfeited.

Common Stock Issued for Services

The Company did not issue any shares of Common Stock in exchange for services during the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026.

Exercise of Stock Options

No stock options were exercised during the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026.

9. STOCK OPTIONS AND WARRANTS

STOCK OPTIONS

During the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026 and ~~2024~~2025, the Company granted no new stock options.

During the same period, 1,022 stock options were forfeited or expired as a result of employee terminations, expiration of option terms, or performance conditions not being met.

WARRANTS

The Company has issued warrants to purchase shares of Common Stock in connection with equity financings and convertible note transactions. The following disclosures summarize warrant issuances, exercises, and outstanding balances for the periods presented.

All share and per-share amounts, including exercise prices and number of warrants, have been retroactively adjusted to reflect the Reverse Stock Split on December 5, 2025.

Significant warrant transactions

On April 27, 2024, the Company entered into a convertible note and warrant purchase agreement with certain investors, pursuant to which the Company issued warrants to purchase shares of Common Stock. On October 18, 2024, holders of such warrants exercised a portion of the warrants on a cashless basis, resulting in the issuance of 55,973 shares of Common Stock. No cash proceeds were received in connection with the cashless exercise.

On January 16, 2025, and January 17, 2025, the Company issued an aggregate of 1,282,051 warrants to purchase Common Stock at an exercise price of $7.80 per share. These warrants had a contractual term of two years and were fully exercised on October 29, 2025.

The following table summarizes warrant activity for the ~~three~~six months ended ~~December~~March 31, ~~2025~~2026:

(Retroactively adjusted for Reverse Stock Split)

	Number of Shares Issuable		Weighted Average Exercise Price		Weighted Average Remaining Life (years)		Aggregate Intrinsic Value
Outstanding on September 30, 2025		1,289,937	$	2,253.40		2.42	$	-
Issued		-		-		-		-
Exercised		1,282,051		7.80		-		-
Expired		-		-		-		-
Outstanding on December 31, 2025		7,886	$	26.19		1.29		-
Exercisable on December 31, 2025		7,886	$	26.19		1.29	$	-

SCHEDULE OF WARRANT ACTIVITY

	Number of Shares Issuable		Weighted Average Exercise Price		Weighted Average Remaining Life (years)		Aggregate Intrinsic Value
Outstanding as of September 30, 2025		1,289,937	$	26.19		1.29	$	-
Issued		-		-		-		-
Exercised		1,282,051		7.80		-		-
Expired		6,298		-		-		-
Outstanding as of March 31,2026		1,588	$	1,125.15		1.37		-
Exercisable as of March 31,2026		1,588	$	1,125.15		1.37	$	-

Reverse Stock Split

On December 2, 2025, the Company filed a Certificate of Change to its Articles of Incorporation with the Secretary of State of the State of Nevada to effect a 1-for-20 ~~reverse~~Reverse ~~stock~~Stock ~~split~~Split of its issued and outstanding Common Stock, which became effective on December 5, 2025. All share and per-share data included in these financial statements have been retroactively adjusted to reflect the Reverse Stock Split.

10. CONTINGENCIES

The Kim Litigation

On October 3, 2024, Mr. Sooncha Kim filed a complaint against the Company in the Southern District of New York, (Case No. 1:24-cv-7485) (the “Kim Complaint”). The Kim Complaint alleges that the Company breached a Convertible Note and Warrant Purchase Agreement, ~~dated~~ dated June 6, 2024, between the Company and Mr. Kim, by, among other things, failing to deliver the registration rights agreement, excluding Mr. Kim from the S-1 registration statement, delaying conversion of Mr. Kim’s notes, undertaking steps to dilute Mr. Kim’s shares, failing to honor Mr. Kim’s 50% participation right in any subsequent financing and failing to appoint a designated director, as set forth in the parties’ agreement. Mr. Kim seeks specific performance of the Convertible Note and Warrant Purchase Agreement, and monetary damages in the amount of $1,041,216, plus applicable interest. The Company filed its answer to the Complaint on December 3, 2024. On January 7, 2025, Mr. Kim filed a motion seeking a preliminary injunction against the Company (the “Motion”). The Company opposed the Motion on January 22, 2025, and on February 13, 2025, the Court denied Mr. Kim’s Motion. As of ~~December~~March 31, ~~2025~~2026, discovery in the case is ongoing, and no trial date has been set.

The Ex-Directors Lawsuit

On March 10, 2025, the following former directors of the Company, Kevin J. Connor, Chris J. Jones, Nobuki Kurita, and David Robson (collectively, the “Ex-Directors”), filed a complaint against the Company in the Superior Court of California, County of San Diego (Case No. 25CU012922N) (the “Ex-Directors Complaint”). The Ex-Directors Complaint alleges the Company failed to pay directors’ fees and expenses from the last quarter the fiscal year ended September 30, 2023 through the first two quarters of the fiscal year ended September 30, 2024, and is claiming breach of contract, quantum meruit, unjust enrichment, promissory estoppel, breach of the implied covenant of good faith and fair dealing, and unfair business practices. On August 22, 2025, a judgment by default was entered against the Company in the amount of $58,920.34. Counsel for Plaintiffs/Judgment Creditors, Kevin J. ~~Conner~~Connor, J. Chris Jones, Nobuki Kurita, and David Robson (collectively, “Plaintiffs”) subsequently filed a motion with the court to amend the total amount of the judgment. On November 21, 2025, the Court entered an order amending the judgment nunc pro tunc, increasing the aggregate awards to all Plaintiffs to $222,062.28, including the prejudgment interest and costs. As the underlying condition existed as of the reporting date, this event represents an adjusting subsequent event, and the related liability has been recognized in Note 4.1510 to the financial statements.

11. SUBSEQUENT EVENTS

~~Convertible~~Approval of the securities purchase agreement ~~Notes~~by and between the Company and High West Partners LLC

On April 10, 2026, ~~February~~the 11Company’s board of directors approved, and on April 14, 2026, the Company’s ~~entered~~majority ~~into~~stockholders aapproved, ~~convertible~~for purposes ~~note~~of ~~and~~complying ~~warrant~~with ~~purchase~~Nasdaq ~~agreement~~Listing ~~with~~Rule ~~certain~~5635(d), ~~non-U.S.~~the ~~investors~~entry ~~providing for~~into a Securities Purchase Agreement (the ~~private~~“Securities Purchase ~~placement~~Agreement”) ofby ~~convertible~~and ~~promissory~~between ~~notes~~the inCompany and High West Partners LLC (the ~~aggregate~~“Investor”), ~~principal~~pursuant ~~amount~~to ofwhich, upon $5execution,~~000~~ the Company may,~~000~~ from time to time and ~~warrants~~in its sole discretion, direct the Investor to purchase shares of the Company’s ~~shares of~~ Common Stock, in ~~reliance~~an onaggregate amount of up to $3,400,000 (the ~~registration~~“Purchase ~~exemptions~~Shares”), at a purchase price equal to (i) 90% of ~~Regulation~~the Slowest .traded ~~The~~price ~~Notes~~of ~~are~~the ~~issuable~~common instock ~~two~~on ~~tranches, consisting~~the applicable purchase date or (ii) 85% of the lowest volume weighted average price (iVWAP) anof ~~initial~~the ~~tranche~~Common inStock during the ~~aggregate~~applicable ~~principal~~pricing ~~amount~~period, subject to a minimum price of $10.01 per share,~~600,000~~ and ~~(ii)~~including athe ~~second~~issuance ~~tranche~~of incommitment ~~the~~shares having an aggregate ~~principal amount~~value of $3200,~~400~~000, with a maximum of 340,000.,000 shares ~~The~~of ~~Notes~~common ~~bear~~stock ~~interest~~issuable atthereunder, anand ~~annual~~with ~~rate~~such ofshares 7%being ~~and~~issuable ~~have~~at a ~~maturity~~discount ~~date~~to ofthe ~~August~~market ~~12,~~price ~~2027~~of the Common Stock.

~~On February~~Primary ~~13,~~offering ~~2026, the Company completed the initial closing~~ and ~~issued~~resale ~~Notes in the aggregate principal amount of $1,600,000 to the Investors.~~prospectus

~~Changes~~The Company filed a registration statement on Form S-1 (File No. 333-294624), as amended, with the SEC on April 28, 2026, which contains disclosure that will be circulated as two separate prospectuses: (i) Primary Offering Prospectus: A prospectus to be used in ~~Registrant~~connection with the offering by the Company of up to 900,000,000 units (the “Units”), each consisting of one share of the Company’s ~~Certifying~~Common ~~Accountant~~Stock, par value $0.00001 per share, and one warrant to purchase one share of Common Stock, and (ii) Resale Prospectus: A prospectus to be used in connection with the offer and sale, from time to time, by certain stockholders named in the Resale Prospectus of up to 43,000,000 shares of Common Stock, at prevailing market prices, prices related to prevailing market prices, or privately negotiated prices.

On February 18, 2026, the Audit Committee of the Board of Directors of CIMG Inc. approved the dismissal of Assentsure PAC as the Company’s independent registered public accounting firm, effective as of such date.28

OnItem ~~February~~2. ~~18, 2026, the Audit Committee approved the engagement of ST & Partners PLT as the Company~~Management’s ~~independent~~Discussion ~~registered public~~and ~~accounting~~Analysis ~~firm~~of ~~for~~Financial ~~the~~Condition ~~fiscal~~and ~~year~~Results ~~ending~~of ~~September 30, 2026~~Operations.

~~Legal~~The ~~Proceedings~~following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This Report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this Report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

~~The~~Although ~~Kim~~the ~~Litigation~~Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

OnOur ~~October~~financial 3,statements ~~2024,~~are ~~Mr.~~prepared ~~Sooncha~~in ~~Kim~~accordance ~~filed~~with aaccounting ~~complaint~~principles ~~against~~generally ~~the~~accepted ~~Company~~ in the ~~Southern~~United ~~District~~States ~~of New York,~~ (~~Case No. 1:24-cv-7485) (the~~ “~~Complaint~~GAAP”). These ~~The~~accounting ~~Complaint~~principles ~~alleges~~require ~~that~~us ~~the~~to ~~Company~~make ~~breached~~certain ~~a Convertible Note and Warrant Purchase Agreement~~estimates, ~~dated June 6~~judgments, ~~2024, between the Company~~ and Mrassumptions. ~~Kim,~~We ~~by,~~believe ~~among~~that ~~other things, failing to deliver~~ the ~~registration rights agreement~~estimates, ~~excluding~~judgments, ~~Mr.~~and ~~Kim~~assumptions ~~from~~upon ~~the~~which ~~S-1~~we ~~registration~~rely ~~statement,~~are ~~delaying~~reasonable ~~conversion~~based ofupon ~~Mr.~~information ~~Kim’s~~available ~~notes, undertaking steps~~ to ~~dilute~~us ~~Mr.~~at ~~Kim’s shares,~~the ~~failing~~time tothat ~~honor~~these ~~Mr.~~estimates, ~~Kim’s 50% participation right in any subsequent financing~~ judgments, and ~~failing~~assumptions toare ~~appoint~~made. aThese ~~designated~~estimates, ~~director~~judgments, as ~~set~~and ~~forth~~assumptions incan affect the ~~parties’~~reported ~~agreement.~~amounts ~~Mr. Kim seeks specific performance~~ of ~~the~~assets ~~Convertible Note~~ and ~~Warrant~~liabilities ~~Purchase~~as ~~Agreement,~~of ~~and monetary damages in~~ the ~~amount~~date of ~~$1,041,216, plus applicable interest. The Company filed its answer to~~ the ~~Complaint~~financial onstatements ~~December 3,~~as ~~2024.~~well Onas ~~January 7, 2025, Mr. Kim filed a motion seeking a preliminary injunction against~~ the ~~Company~~reported ~~(the~~amounts ~~“Motion”). The~~of ~~Company~~revenues ~~opposed the Motion on January 22, 2025,~~ and onexpenses ~~February~~during ~~13, 2025,~~ the ~~Court~~periods ~~denied Mr~~presented. ~~Kim’s~~Our ~~Motion.~~financial statements Aswould ofbe ~~December~~affected ~~31,~~to ~~2025, discovery in~~ the ~~case~~extent isthere ~~ongoing,~~are ~~and~~material nodifferences ~~trial~~between ~~date~~these ~~has been set~~estimates.

The ~~Ex-Directors~~following ~~Lawsuit~~discussion should be read in conjunction with our unaudited financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q.

On March 10, 2025, the following former directors of the Company, Kevin J. Connor, Chris J. Jones, Nobuki Kurita, and David Robson (collectively, the “Ex-Directors”), filed a complaint against the Company in the Superior Court of California, County of San Diego (Case No. 25CU012922N) (the “Complaint”). The Complaint alleges the Company failed to pay directors’ fees and expenses from the last quarter the fiscal year ended September 30, 2023 through the first two quarters of the fiscal year ended September 30, 2024, and is claiming breach of contract, quantum meruit, unjust enrichment, promissory estoppel, breach of the implied covenant of good faith and fair dealing, and unfair business practices. On August 22, 2025, a judgment by default was entered against the Company in the amount of $58,920.34. Counsel for Plaintiffs/Judgment Creditors, Kevin J. Conner, J. Chris Jones, Nobuki Kurita, and David Robson (collectively, “Plaintiffs”) subsequently filed a motion with the court to amend the total amount of the judgment. On November 21, 2025, the Court entered an order amending the judgment nunc pro tunc, increasing the aggregate awards to all Plaintiffs to $222,062.28, including the prejudgment interest and costs. As the underlying condition existed as of the reporting date, this event represents an adjusting subsequent event, and the related liability has been recognized in Note 4.15 to the financial statements.Overview

~~New~~CIMG ~~Subsidiaries~~is a company incorporated in Nevada and has been listed on Nasdaq since June 2020. We were formerly known as “Nuzee, Inc.” with a previous ticker symbol “NUZE”, and we changed our corporate name and ticker symbol to “CIMG Inc.” and “IMG” in October 2024. We previously focused on specialty coffee and related technologies, but we are now expanding our sales and distribution channels in Asia to provide a wider variety of healthy foods to Asian customers. We also help our customers and distributors maximize user growth and product sales through AI computing technology. These AI services have supported our expansion in Asia.

OnSince ~~February~~July 42024, ~~2026,~~we ~~Beijing~~have ~~Xin~~been ~~Miao~~undergoing ~~Shi~~a ~~Dai~~transformation ~~Technology~~in ~~Development~~digital ~~Co.~~marketing, ~~Ltd~~distribution, and sales. ~~established~~As apart ~~wholly~~of this transformation, we have expanded our sales and distribution network to include Maca-~~owned~~enhanced ~~subsidiary~~food and beverages, ~~Foshan~~reaffirming ~~Dingyue~~our ~~Technology~~commitment to reshaping ~~Co.~~the online marketing, ~~Ltd~~sales, and distribution landscape for consumer products.

OnMaca, ~~February~~a 5,plant ~~2026,~~in ~~Zhongyan~~the ~~Shangyue~~Brassicaceae ~~Technology~~family ~~Co.~~that originated in South America, ~~Ltd~~has oval leaves and a root that resembles a small round radish. It ~~established~~is edible and is widely regarded as a ~~wholly-owned~~natural ~~subsidiary~~“superfood” Maca is rich in nutrients and is believed to nourish and strengthen the human body, ~~Foshan~~and ~~Lintai~~it ~~Technology~~is Cooften referred to as “South American ginseng”. The primary cultivation regions for Maca include the Andes Mountains in South America and the Jade Dragon Snow Mountain area in Lijiang, ~~Ltd~~Yunnan, China.

We have secured exclusive distribution and sales rights in Asia for a three-year term for “Kangduoyuan” brand Maca products. The product portfolio under this agreement includes Maca Peptide Coffee, Maca-Noni, Maca Wine, Maca Purified Powder, and other Maca-related offerings. We promote these products through a digital marketing strategy and online sales channels, which has supported our Maca series growth.

Since July 2024, we launched the “Homology of Medicine and Food” series including Huomao-branded products, exosome eye drops and other health and wellness products. The Homology of Medicine and Food Series is guided by traditional Chinese medicine theory, incorporates modern nutritional principles to identify the functional attributes of certain foods and food-derived ingredients. We are committed to providing healthier and more suitable health and wellness products for Asian customers. The launch of the new product effectively contributed to the growth of our sales.

We source, market, and distribute health and wellness products, including Maca-based dietary supplements, functional foods, and beauty products. We leverage technology and data-driven marketing tools to support product promotion and sales. We are committed to providing high-quality products with a focus on responsible and sustainable sourcing to consumers seeking to enhance their health and wellness. We sell our products through online channels and a network of retail partners, including grocery stores, convenience stores, and vending machines.

Since September 2025, we launched the “Computing Power Product” series. We provide customers with hardware devices, such as GPUs integrated with artificial intelligence data-processing modules. These modules are embedded in the GPUs and tailored to the characteristics and needs of each industry. The modules enable industry-specific data learning, helping applications develop more accurate data-processing patterns, and intelligently complete operational tasks. We primarily sell these products to business customers, who then integrate them into their own servers, core processors, and other computing infrastructure and deliver solutions to their end users. We continuously refine our artificial intelligence data-processing templates and enhance the learning capabilities of the modules to deliver more accurate intelligent services across a broad range of industries.

~~Item~~The 2.diagram ~~Quantitative~~below ~~and~~is ~~Qualitative~~our ~~Disclosures~~corporate ~~About~~structure ~~Market~~as ~~Risk~~of the date of this Report.

Our sources of revenue

(i) The Maca Series

In the fourth quarter of the fiscal year ended September 30, 2024, we launched our health-focused product line in Asia, the Maca Series.

Maca, a plant native to South America and a member of the Brassicaceae family, is known for its nutritional value and adaptogenic properties. Often referred to as “South American ginseng,” Maca is prized for its ability to support stamina, vitality, and overall wellness. It is primarily cultivated in the Andes Mountains in South America, and Jade Dragon Snow Mountain in Yunnan Province, China.

As of the date of this Report, our Maca Series product line includes Maca Peptide Coffee, Maca-Noni, Maca Purified Powder, and Maca Wine. Each product features green purification factors derived from the Maca plant, resulting in a natural and clean composition.

Maca Peptide Coffee

Our Maca Peptide Coffee is characterized by a strong yet smooth, non-bitter taste with a subtle fruity aroma. It is medium-roasted and contains no added sugar, preserving its original flavor profile. The primary ingredients include Maca peptide, yellow essence, and Malaysian white coffee. In our formulation, coffee is added mainly to enhance flavor and provide a familiar coffee taste, while the functional attributes are derived primarily from Maca and yellow essence.

We use high-quality Maca grown at altitudes of no less than 3,200 meters, with an average yield of approximately 70 kilograms per mu. The Maca is cultivated without the use of pesticides, fertilizers, or growth enhancers. To maximize potency, harvesting occurs only after the leaves have turned brown, which is intended to ensure the effectiveness of the raw material.

Maca-Noni

Maca-Noni is a Maca-enhanced, plant-based energy drink that is intended for consumption scenarios similar to those of traditional energy drinks, such as Red Bull. It is positioned as a plant-based beverage alternative to traditional energy drinks and is marketed for general lifestyle consumption. Unlike traditional energy drinks, Maca-Noni is primarily made from Maca extracts and does not contain caffeine. As a result, it is positioned as a healthier alternative to conventional energy drinks, and long-term consumption may offer additional wellness benefits.

The initial batch of Maca-Noni plant-based energy drinks is offered in 250 ml cans, with packaging designed to appeal to younger consumers. The packaging adopts a “professional role” design concept, incorporating representations of 66 professions and 132 facial expressions drawn from target consumer groups, including drivers, workers, students, athletes, fitness enthusiasts, lawyers, doctors, live streamers, and e-commerce operators, adding emotional engagement and storytelling elements to the product.

We emphasize quality, sustainability, and transparency in the sourcing and production of our Maca. Our Maca is primarily sourced from Yunnan, China, where it is cultivated in high-altitude regions that are favorable for Maca growth. We work closely with Jiangsu Kangduoyuan Beverage Co., Ltd. to promote sustainable sourcing practices and fair-trade standards.

Maca Purified Powder

Maca Purified Powder is positioned as a nutritional supplement and contains protein, amino acids, polysaccharides, minerals, and certain bioactive compounds, such as Macamides and Macalenes. These components are commonly associated with general nutritional support. The product is formulated using natural ingredients and is marketed as part of a balanced diet and healthy lifestyle. In addition, antioxidant-related components are commonly associated with supporting overall wellness and skin condition. We do not make medical claims or offer medical products.

We currently distribute our Maca Series products primarily through wholesale channels, supplying grocery stores, convenience stores, and vending machine operators. Going forward, we plan to expand our retail operations and leverage digital technologies to enhance marketing effectiveness and diversify our sales models. Our distribution network spans both online platforms and offline points of sale.

Our commitment extends beyond product quality to brand presentation and packaging design. We focus on creating packaging that resonates with professionals across various industries, making our products more personalized, youthful, and distinctive. For example, Maca-Noni is a newer addition to our functional beverage offerings, combining health-focused branding with an updated and innovative design.

Maca Wine is an alcoholic beverage formulated with Maca and is marketed as a specialty wellness-oriented product with a distinctive flavor profile. It is positioned for social and family dining occasions, where it is consumed as part of meals and gatherings. The product is promoted for its taste characteristics and its association with traditional wellness concepts.

Maca Wine is inspired by traditional dietary and wellness practices and is marketed as a daily wellness beverage when consumed in moderation. It is not intended to diagnose, treat, cure, or prevent any disease. Moderate consumption is promoted as part of a balanced lifestyle. We do not make medical claims with respect to Maca Wine or any of our products.

(ii) The Homology of Medicine and Food Series

In the fourth quarter of 2025, we expanded our product offerings in Asia to include The Homology of Medicine and Food Series, including Huomao-branded products, exosome eye drops, and other health and wellness products. We expanded our sales channels and diversified our product portfolio through the acquisition of subsidiaries, enabling us to offer Asian customers a broader range of health and wellness products. For example, we acquired Shanghai Huomao, which provided us with Huomao-branded products such as Huomao liquor. The Homology of Medicine and Food Series is guided by traditional Chinese medicine theory, incorporates modern nutritional principles to identify the functional attributes of certain foods and food-derived ingredients. We do not offer medical products or provide medical advice; rather, we are committed to providing healthier and more suitable health and wellness products for Asian customers.

We currently distribute our Homology of Medicine and Food Series products through wholesale channels. Looking ahead, we plan to expand into retail services and leverage digital technologies to optimize marketing strategies and diversify our sales models. Our distribution network already spans both online platforms and offline points of sale.

The exosome eye drops contributed the largest share of revenue among all Homology of Medicine and Food series products. The exosome eye drops are a type of soothing eye drops. Their core technology is derived from living cells of exosomes, and they do not contain hormones or antibiotics. The exosome eye drops have the effects of relieving fatigue, improving pseudo-myopia and reducing eye dryness. For users, exosome eye drops will be helpful in alleviating eye discomfort when spending long periods in front of electronic devices such as computers and mobile phones, and will contribute to protecting eye health.

(iii) Computing Power Product Series

We provide distributors and other business customers in Asia with hardware devices, such as GPUs integrated with artificial intelligence-enabled data-processing modules, together with data analytics and marketing support services. The data-processing modules are embedded in the GPUs and tailored to the characteristics of each industry. These modules provide industry-specific data learning capabilities, help applications develop more accurate data-processing patterns, and intelligently complete operational tasks.

Our Customers

Our customers include wholesale distributors, such as grocery stores, convenience stores, and vending machine operators.

Maca Series: We sell the Maca Series products to wholesale distributors, such as grocery stores, convenience stores, and vending machine operators.

The Homology of Medicine and Food Series: We sell the Homology of Medicine and Food Series products to wholesale distributors.

The Computing Power Product series: We sell hardware devices, such as GPUs embedded with artificial intelligence data-processing modules, to enterprise customers such as China Merchants Bank.

Our Suppliers

Our suppliers include raw material providers, finished product providers, and research and development service providers.

Maca Series: We purchase maca raw materials from raw material suppliers and entrust a third party to process them into maca series products for sale.

The Homology of Medicine and Food Series: In addition to acquiring subsidiaries to independently produce the Homology of Medicine and Food products, we also screen high-quality finished product providers to provide healthy and suitable products for Asian customers.

The Computing Power Product Series: In addition to independently developing core technologies, technology providers provide us with application services for computing power technology.

Nasdaq Listing Deficiency

On January 22, 2026, the Company received a letter from Nasdaq indicating that the Panel will consider an additional basis for the potential delisting of the Company’s securities from The Nasdaq Capital Market during the panel monitor period because the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2025. On February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the SEC.

On February 23, 2026, the Company received a letter from Nasdaq indicating that the Panel will consider the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1), due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended December 31, 2025 (the “2025 1231 Form 10-Q”), as an additional basis for the potential delisting of the Company’s securities from The Nasdaq Capital Market during the Panel’s monitor period (in a decision letter dated December 4, 2025, the Panel imposed a Mandatory Panel Monitor with respect to the Company pursuant to Nasdaq Listing Rule 5815(d)(4)(B), which requires Nasdaq Staff to issue a delisting determination if the Company fails to maintain compliance during the monitoring period. The Mandatory Panel Monitor will remain in effect until November 14, 2026). On March 5, 2026, the Company filed the 2025 1231 Form 10-Q with the SEC.

On March 4, 2026, the Company received a written notice from Nasdaq that the Panel had determined to delist the Company’s Common Stock from The Nasdaq Stock Market due to the Company’s failures to comply with Nasdaq Listing Rules 5550(a)(2), 5250(c)(1), 5550(b)(1), and 5620(a). Trading in the Company’s Common Stock was suspended at the open of trading on March 6, 2026. The Company has appealed the Panel’s decision to request that the Nasdaq Listing and Hearing Review Council review the Panel’s decision. There can be no assurance that any such appeal will be successful. If the appeal is unsuccessful, Nasdaq is expected to file a Form 25 with the SEC to remove the Company’s Common Stock from listing and registration on The Nasdaq Stock Market. As of the date of this Report, the appeal process is still ongoing.

On March 6, 2026, the Company received a letter from Department of Market Operations of the Financial Industry Regulatory Authority, Inc. (“FINRA”), dated March 5, 2026, notifying the Company that the symbol “CIMG” had been assigned to the Common Stock. As of March 6, 2026, the Common Stock may be quoted and traded in the over-the-counter market under the symbol “CIMG.”

Results of Operations (comparison of the three months ended March 31, 2026 and 2025)

Revenue

	Three months ended March 31,				Change
	2026		2025		Dollars		%
Revenue	$	3,214,991	$	-	$	3,214,991		-	%

For the three months ended March 31, 2026, the Homology of Medicine and Food Series, Computing Power Product Series, and Maca Product Series generated revenues of $428,786, $2,649,785, and $136,420 respectively, accounting for 13.34%, 82.42%, and 4.24% of the total revenue. Our total revenue was $3,214,991 for the three months ended March 31, 2026 and it was $nil for the three months ended March 31, 2025. The significant increase in revenue was mainly due to the sale of maca inventory and the additional revenue generated by the new medical and food homology product series as well as the computing power product series.

Cost of sales and gross margin

	Three months ended March 31,						Change
	2026			2025			Dollars		%
Cost of revenue	$	3,201,338		$	-		$	3,201,338		-	%
Gross profit		13,653		$	-		$	13,653		-	%
Gross profit %		0.42	%		-	%		-		-

For the three months ended March 31, 2026, the total sales cost was $3,201,338. For the three months ended March 31, 2025, the total sales cost was $nil. The significant increase in the cost of revenue was mainly due to the corresponding cost growth of the Maca series products and the inclusion of the Homology of Medicine and Food Series and the Computing Power Product Series.

For the three months ended March 31, 2026, the total gross profit reached $13,653, with a gross profit margin of 0.42%. In contrast, for the three months ended March 31, 2025, the gross profit was $nil, with a gross profit margin of Nil.

Operating Expenses

	Three months ended March 31,				Change
	2026		2025		Dollars		%
Operating Expenses	$	1,337,791	$	752,677	$	585,114		77.74	%

For the three months ended March 31, 2026, the total operating expenses amounted to $1,337,791. For the three months ended March 31, 2025, the total operating expenses amounted to $752,677. The figure increased by $585,114, representing a growth rate of 77.74%. This was mainly due to the rise in labor costs and professional expenses (including legal and consulting service fees).

Net Loss

	Three months ended March 31,				Change
	2026		2025		Dollars		%
Net Loss	$	15,434,637	$	385,556	$	15,049,081		3903.22	%

For the three months ended March 31, 2026, we incurred a net loss of $15,434,637, compared to a net loss of $385,556 for the same period of 2025. The increase in net loss was mainly attributed to the rise in labor costs and professional expenses (including legal and consulting service fees) as well as the fair value measurement of digital assets.

Comparison of the six months ended March 31, 2026 and 2025

Revenue

	Six months ended March 31,				Change
	2026		2025		Dollars		%
Revenue	$	18,983,787	$	22,853	$	18,960,934		82,969.12	%

For the six months ended March 31, 2026, the Homology of Medicine and Food Series, Computing Power Product Series, and Maca Product Series generated revenues of $1,855,618, $5,010,158, and $12,118,011 respectively, accounting for 9.78%, 26.39%, and 63.83% of the total revenue. Our total revenue was $18,983,787 for the six months ended March 31, 2026 and it was $22,853 for the six months ended March 31, 2025, representing a growth of 82,969.12%. The significant increase in revenue was mainly due to the sale of maca inventory and the additional revenue generated by the new medical and food homology product series as well as the computing power product series.

Cost of sales and gross margin

	Six months ended March 31,						Change
	2026			2025			Dollars		%
Cost of revenue	$	18,882,718		$	7,374		$	18,875,344		255,971.58	%
Gross profit		101,069		$	15,479		$	85,590		552.94	%
Gross profit %		0.53	%		67.73	%		-		-

For the six months ended March 31, 2026, the total sales cost was $18,882,718. For the six months ended March 31, 2025, the total sales cost was $7,374. This figure increased by 255,971.58%. The significant increase in the cost of revenue was mainly due to the corresponding cost growth of the Maca series products and the inclusion of the Homology of Medicine and Food Series and the Computing Power Product Series.

For the six months ended March 31, 2026, the total gross profit reached $101,069, with a gross profit margin of 0.53%. In contrast, for the six months ended March 31, 2025, the gross profit was $15,479, with a gross profit margin of 67.73%. The decline in the gross profit margin was mainly due to the sale of the maca series at discounted prices and the increased proportion of revenue from the Homology of Medicine and Food Series and Computing Power Product Series.

Operating Expenses

	Six months ended March 31,				Change
	2026		2025		Dollars		%
Operating Expenses	$	3,417,780	$	2,270,435	$	1,147,345		50.53	%

For the six months ended March 31, 2026, the total operating expenses amounted to $3,417,780. For the six months ended March 31, 2025, the total operating expenses amounted to $2,270,435 The figure increased by $1,128,643, representing a growth rate of 50.53%. This was mainly due to the rise in labor costs and professional expenses (including legal and consulting service fees).

Net Loss

	Six months ended March 31,				Change
	2026		2025		Dollars		%
Net Loss	$	34,860,910	$	1,921,805	$	32,939,105		1713,97	%

For the six months ended March 31, 2026, we incurred a net loss of $34,860,910, compared to a net loss of $1,921,805 for the same period of 2025. The increase in net loss was mainly attributed to the rise in labor costs and professional expenses (including legal and consulting service fees) as well as the fair value measurement of digital assets.

Liquidity and Capital Resources

Since our inception in 2011, we have incurred significant losses, and as of March 31, 2026, we had an accumulated deficit of approximately $122.10 million. We have not yet achieved profitability and anticipate that we will continue to incur significant sales and marketing expenses prior to recording sufficient revenue from our operations to offset these expenses. In the United States, we expect to incur additional losses because of the costs associated with operating as an exchange-listed public company. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

As of the date of this Report, the Company has funded its operations primarily through proceeds from registered public offerings and private placements of its Common Stock. The Company’s principal uses of cash include funding operations, product commercialization and development activities, administrative support, and working capital requirements.

As of March 31, 2026, the Company had a cash balance of $17,025 and has incurred recurring net losses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of this Report.

Management has evaluated the Company’s ability to continue as a going concern by considering its current cash resources, the value of its digital assets, and its expected operating expenses over the next twelve months. Management’s plans to alleviate the conditions giving rise to substantial doubt include seeking additional funding through public or private equity financings, equity-linked instruments, or other capital-raising activities. The timing and availability of such funding are subject to market conditions and other factors, including the potential exercise of outstanding warrants by warrant holders.

There can be no assurance that such financing will be available on acceptable terms, or at all. Accordingly, management has concluded that substantial doubt about the Company’s ability to continue as a going concern has not been alleviated.

Summary of Cash Flows

	Six Months Ended March 31,
	2026			2025
Cash used in operating activities	$	(10,129,033	)	$	(10,294,334	)
Cash provided by (used in) investing activities		(160	)		12,767
Cash provided by financing activities	$	10,053,075		$	10,074,304
Effect of foreign exchange on cash	$	(44,144	)	$	(254,555	)
Net change in cash	$	(120,262	)	$	(461,818	)

Operating Activities

Net cash used in operating activities from continuing operations was $10,129,033 for the six months ended March 31, 2026. The cash outflows were primarily related to purchases digital assets and other professional expenses including legal fees.

Net cash used in operating activities from continuing operations was $10,294,334 for the six months ended March 31, 2025. The cash outflows were primarily related to purchases of raw materials and inventory, office rent, legal fees, and other professional expenses.

Investing Activities

Net cash used in investing activities totaled $160 for the six months ended March 31, 2026, compared with net cash provided by investing activities of $12,767 in the corresponding 2025 period. The current period’s cash outflows from investing activities were primarily attributable to the disposal of subsidiaries, whereas the prior-year period’s cash inflows stemmed mainly from subsidiary acquisitions and the sale of property and equipment.

Financing Activities

Historically, we have funded our operations through the issuance of our equity securities.

Net cash provided by financing activities was $10,053,075 for the six months ended March 31, 2026, primarily attributable to the gains from convertible notes and the issuance of warrants. For the six months ended March 31, 2025, net cash provided by financing activities was $10,074,304 primarily attributable to proceeds from private placement and issuance of Common Stock.

Off-Balance Sheet Arrangements

As of March 31, 2026, we had no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements that have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). As discussed in “Note 2—Basis of Presentation and Summary of Significant Accounting Policies” to the Consolidated Financial Statements, the preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. US GAAP provides the framework from which to make these estimates, assumptions and disclosures. We choose accounting policies within US GAAP that management believes are appropriate to accurately and fairly report our operating results and financial position in a consistent manner. Management regularly assesses these policies in light of current and forecasted economic conditions. See the “Note 2—Basis of Presentation and Summary of Significant Accounting Policies” to the Consolidated Financial Statements for a summary of our accounting policies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

Item 34. Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by our Company is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is collected and communicated to management, including our Chief Executive ~~Officer~~Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our Chief Executive ~~Officer~~Officers and Chief Financial Officer are responsible ~~for~~ for establishing and maintaining disclosure controls and procedures for our Company. In designing and evaluating our disclosure controls and procedures, management recognizes that no matter how well conceived and operated, disclosure controls and procedures can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

Our management, ~~including~~with the participation of our Chief Executive Officer and Chief Financial Officer, iscarried ~~responsible~~out ~~for~~an ~~establishing~~evaluation ~~and~~of ~~maintaining~~the ~~adequate internal~~effectiveness ~~control~~of ~~over~~our ~~financial~~“disclosure ~~reporting~~controls and procedures” (as defined in Exchange Act Rules 13a-15(fe) and 15d-15(fe).) ~~Our~~as ~~internal~~of ~~control~~March 31, ~~system~~2026, ~~was~~the ~~designed to~~end ~~provide~~of ~~reasonable~~the ~~assurance~~period tocovered by this Report (the “Evaluation Date”). Based upon that evaluation, our ~~management~~Chief Executive Officer and ~~board~~Chief ofFinancial ~~directors~~Officer ~~regarding~~concluded that, as of the ~~preparation~~Evaluation Date, our disclosure controls and ~~fair~~procedures ~~presentation~~were ofnot ~~published~~effective, ~~financial~~at ~~statements.~~the ~~Our~~reasonable ~~management~~assurance ~~assessed~~level, ~~the~~to ~~effectiveness~~ensure ofthat ~~the~~information ~~Company’s~~required ~~internal~~to ~~control~~be ~~over~~disclosed ~~financial~~by ~~reporting~~us asin of the ~~end~~reports ofthat we file or submit under the ~~period~~Exchange ~~covered~~Act by(i) ~~this~~is ~~Report~~recorded, ~~based~~processed, onsummarized ~~the~~and ~~criteria~~reported, ~~for~~within ~~effective~~the ~~internal~~time ~~control~~periods ~~described~~specified in ~~Internal~~the ~~Control-Integrated Framework~~SEC rules and forms and (~~2013~~ii) ~~issued~~is byaccumulated ~~the~~and ~~Committee~~communicated ofto ~~Sponsoring~~our ~~Organization~~management, ofincluding ~~the~~our ~~Treadway~~Chief ~~Commission.~~Executive ~~Based~~Officer onand ~~this~~Chief ~~assessment~~Financial Officer, ~~our~~as appropriate ~~management~~to ~~has~~allow ~~concluded~~timely ~~that~~decisions regarding required disclosure and (iii) because of the ~~Company’s~~inherent ~~internal~~limitations in our control ~~over~~system, ~~financial~~misstatements due ~~reporting~~to ~~was~~error or fraud may occur and not be detected. We cannot assure you that the measures we have taken will be effective asin ofmitigating or ~~December~~preventing ~~31,~~significant ~~2025~~deficiencies or material weaknesses in our internal control over financial reporting in the future.

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. Our management assessed the effectiveness of the Company’s internal control over financial reporting as of the end of the period covered by this Report based on the criteria for effective internal control described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organization of the Treadway Commission (COSO). Based on this assessment, our management has concluded that the Company’s internal control over financial reporting was not effective as of March 31, 2026.

As we are a non-accelerated filer, our independent registered public accounting firm is not required to issue an attestation report on our internal control over financial reporting.

There were no changes in our internal control over financial reporting that occurred during the quarterly period ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended ~~December~~March 31, ~~2025~~2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3034

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

Refer to “Note 10. Contingencies” and “Note 11. Subsequent Events—Legal Proceedings” in our Consolidated Financial Statements included in this Report.

Item 1A. RISK FACTORS

In addition to the other information set forth in this Report, you should carefully consider the risk factors discussed in “Item 1A-—Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on February 13, 2026, as well as the risk factors included in our Registration Statement on Form S-1, as amended, most recently filed with the SEC on April 29, 2026 (File No. 333-294624), which could affect our business, financial condition, or operating results. The risks described in our annual, or quarterly, ~~reports~~and ~~filed~~registration statement filings with the SEC are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition, or operating results. For the three months ended ~~December~~March 31, ~~2025~~2026, we were not aware of any new and additional risk factors that were not previously disclosed.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) ~~Subsequent~~During to the quarter ended ~~December~~March 31, ~~2025~~2026, the Company completed the following unregistered issuances of its equity securities:

On February 11, 2026, the Company entered into a convertible note and warrant purchase agreement (the “February Purchase Agreement”) with certain non-U.S. investors (the “February Investors”), providing for the private placement of convertible promissory notes in the aggregate principal amount of up to $5,000,000 (the “February Notes”) and warrants to purchase the Company’s shares of Common Stock (the “February Warrants”) in reliance on Regulation S as an exemption tofrom ~~the~~ registration (the “February Transaction”). The ~~Notes~~February ~~are~~Purchase ~~issuable~~Agreement inoriginally contemplated two tranches, consisting of (i) an initial tranche in the aggregate principal amount of $1,600,000 and (ii) a second tranche in the aggregate principal amount of $3,400,000. The ~~Notes~~February Notes issued in the first tranche bear interest at an annual rate of 7% and have a maturity date of August 12, 2027. On February 13, 2026, the Company completed the initial closing and issued February Notes in the aggregate principal amount of $1,600,000 to the February Investors. As of the date of this Report, none of the February Warrants has been exercised, none of the February Notes has been converted, and no shares of Common Stock have been issued pursuant to the February Transaction.

On March 21, 2026, the Company entered into an Amended and Restated Convertible Note and Warrant Purchase Agreement with the February Investors, pursuant to which the parties amended and restated the February Purchase Agreement. In connection with the amendment, the parties agreed to cancel the second closing contemplated under the original agreement, and the Company issued amended notes and amended and restated warrants to the February Investors. The amended notes include a conversion price floor of $0.10 per share, and the amended and restated warrants are exercisable for cash only at an exercise price of $0.015 per share. The Company also agreed to file a registration statement covering the resale of the shares issuable upon conversion of the amended notes and exercise of the amended and restated warrants.

As of the date of this Report, none of the February Warrants, as amended and restated, has been exercised, none of the February Notes, as amended, has been converted, and no shares of Common Stock have been issued pursuant to the February Transaction.

On February 27, 2026, the Company entered into an Amended and Restated Equity Transfer Agreement (the “A&R Equity Transfer Agreement”) with DZR Tech Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “Purchaser”), Shelei Jiang, a Chinese individual (the “Seller”), and Daren Business Technology Limited, a company incorporated under the laws of the British Virgin Islands (the “Target”). The A&R Equity Transfer Agreement amended and restated in its entirety that certain Equity Transfer Agreement, dated February 11, 2026, by and between the Seller and the Purchaser. Pursuant to the A&R Equity Transfer Agreement, the Seller agreed to sell to the Purchaser 100 ordinary shares of the Target, representing 100% of the issued and outstanding ordinary shares of the Target, for a purchase price of zero cash consideration (the “Acquisition”). The Acquisition closed on March 12, 2026, and, on the same date, the Company issued the Award Shares described below.

On March 10, 2026, the Company and each of Dundas Technology Limited and Kellyview Investment Limited, each a Hong Kong company and a designee of the Seller pursuant to the terms of the A&R Equity Transfer Agreement, entered into a separate performance share issuance agreement, pursuant to which the Company agreed to issue to Dundas Technology Limited and Kellyview Investment Limited, in the aggregate up to 74,487,896 shares of the Company’s Common Stock, par value $0.00001 per share (the “Award Shares”), with one-half of the Award Shares to be issued to Dundas Technology Limited and one-half to Kellyview Investment Limited, as a post-closing, performance-based equity award with respect to the Target. On March 12, 2026, the Company issued 37,243,948 shares of Common Stock to Dundas Technology Limited and 37,243,948 shares of Common Stock to Kellyview Investment Limited. Such shares will be subject to transfer restrictions and will be eligible for leak-out in installments only upon the achievement of specified audited revenue targets of the Target during performance periods beginning on April 1, 2026 and ending on September 30, 2029.

(b) None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

During the three months ended ~~December~~March 31, ~~2025~~2026, none of the Company’s directors or officers, as defined in Section 16 of the Securities Exchange Act of 1934, adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined under Item 408(a) of Regulation S-K.

Amendments to Articles of Incorporation or Bylaws

On March 5, 2026, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to increase the number of authorized shares of the Company’s Common Stock. The amendment increased the Company’s authorized shares of Common Stock from 600,000,000 shares to 2,000,000,000 shares, par value $0.00001 per share.

Item 6. EXHIBITS

Exhibit Number		Description
3.1		Articles of Incorporation of the Company, dated July 15, 2011 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed on December 23, 2022, SEC File Number 001-39338).
3.2		Certificate of Amendment to Articles of Incorporation of the Company, dated May 6, 2013 (incorporated by reference to Exhibit 3.01(b) to the Company’s Current Report on Form 8-K filed on April 25, 2013, SEC File Number 333-176684).
3.3		Certificate of Amendment to Articles of Incorporation of the Company, dated October 28, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 28, 2019, SEC File Number 000-55157).
3.4		Certificate of Amendment of Amended and Restated Certificate of Incorporation filed on October 22, 2024. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 28, 2024, SEC File Number 001-39338).
3.5		Certificate of Amendment to the Articles of Incorporation of the Company, dated October 28, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 31, 2025, SEC File No. 001-39338).
3.6		Certificate of Change to the Articles of Incorporation of the Company, dated December 2, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 5, 2025, SEC File No. 001-39338).
3.7		Third Amended and Restated Bylaws of the Company, effective March 17, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 23, 2022, SEC File Number 001-39338).
3.8		Certificate of Amendment, dated March 5, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 12, 2026, SEC File Number 001-39338).
4.1		Description of Securities (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on December 23, 2022, SEC File Number 001-39338).
4.2		Series A Warrant Agent Agreement (including the terms of the Series A Warrant) (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March 23, 2021, SEC File Number 001-39338).
4.3		Series B Warrant Agent Agreement (including the terms of the Series B Warrant) (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on March 23, 2021, SEC File Number 001-39338).
4.4		Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 15, 2022, SEC File Number 001-39338).
4.5		Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 2, 2024, SEC File Number 001-39338)
4.6		Form of Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on December 17, 2024, SEC File Number 001-39338)
4.7		Form of Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)
4.8		Form of Amended and Restated Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on March 25, 2026, SEC File Number 001-39338)
10.1		CIMG Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Company’s Annual Report on Form 10-K filed on February 13, 2026, SEC File Number 001-39338)
10.2		CIMG Inc. 2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K filed on February 13, 2026, SEC File Number 001-39338)
10.3		Purchase Agreement, dated February 11, 2026, by and among the Company and the Investors party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)
10.4		Amended and Restated Equity Transfer Agreement, dated February 27, 2026, by and among the Company, DZR Tech Limited, Shelei Jiang, and Daren Business Technology Limited (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 5, 2026, SEC File Number 001-39338)
10.5		Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)

3136

3.4		Certificate of Amendment of Amended and Restated Certificate of Incorporation filed on October 22, 2024. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 28, 2024, SEC File Number 001-39338).
10.6		Performance Share Issuance Agreement between the Company and Dundas Technology Limited, dated March 10, 2026 (incorporated by reference to Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q/A filed on March 19, 2026, SEC File Number 001-39338)
3.5		Certificate of Amendment to the Articles of Incorporation of the Company, dated October 28, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 31, 2025, SEC File No. 001-39338).
10.7		Performance Share Issuance Agreement between the Company and Kellyview Investment Limited, dated March 10, 2026 (incorporated by reference to Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q/A filed on March 19, 2026, SEC File Number 001-39338)
3.6		Certificate of Change to the Articles of Incorporation of the Company, dated December 2, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 5, 2025, SEC File No. 001-39338).
10.8		Amended and Restated Convertible Note and Warrant Purchase Agreement, dated as of March 21, 2026, by and among CIMG Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 25, 2026, SEC File Number 001-39338)
3.7		Third Amended and Restated Bylaws of the Company, effective March 17, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 23, 2022, SEC File Number 001-39338).
10.9		Form of Amendment No. 1 to Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 25, 2026, SEC File Number 001-39338)
4.1		Description of Securities (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on December 23, 2022, SEC File Number 001-39338).
4.2		Series A Warrant Agent Agreement (including the terms of the Series A Warrant) (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March 23, 2021, SEC File Number 001-39338).
4.3		Series B Warrant Agent Agreement (including the terms of the Series B Warrant) (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on March 23, 2021, SEC File Number 001-39338).
4.4		Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 15, 2022, SEC File Number 001-39338).
4.5		Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 2, 2024, SEC File Number 001-39338)
4.6		Form of Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on December 17, 2024, SEC File Number 001-39338)
4.7		Form of Warrant (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)
10.1		CIMG Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Company’s Annual Report on Form 10-K filed on February 13, 2026, SEC File Number 001-39338)
10.2		CIMG Inc. 2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K filed on February 13, 2026, SEC File Number 001-39338)
10.3		Purchase Agreement, dated February 11, 2026, by and among the Company and the Investors party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)
10.4		Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)
31.1*		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

*	Filed herewith.

**	Furnished herewith. This exhibit will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

3237

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CIMG INC.
Date: March 5, 2026	By:	/s/ Jiangshuang Wang
Date: May 11, 2026	By:	/s/ Jianshuang Wang
		Jianshuang Wang
		Chief Executive Officer
		(Principal Executive Officer)
	By:	/s/ Feng Tian
		Feng Tian
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

3338

Filing Compare · CIMG Inc.